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Abstract 
Introduction 
Retention-in-care and adherence to lifelong antiretroviral therapy (ART) are major requirements to 
successfully optimise treatment benefits. We assessed linkage and retention-in-care with 
adherence and determinants of poor adherence along the PMTCT cascade in HIV-positive pregnant 
and breastfeeding women initiating option B+ in Cameroon. 
Materials and Methods 
We prospectively determined uptake of HIV testing and counselling (HTC), uptake of ART, 
retention-in-care and adherence after Option B+ initiation between October 2013 and December 
2014 in pregnant and breastfeeding women from five sites within the Kumba Health District. 
Retention-in-care was assessed over at least 12 months follow-up and estimated by Kaplan Meier 
analysis. Adherence at 12 months was determined for women retained in care using a composite 
adherence score. During follow-up, tracing outcomes and reasons for discontinuing treatment were 
documented and adherence measured. 
 
Results 
Uptake of HTC in 5,813 women with unknown HIV status was 98.5% and ART uptake in women 
eligible to start Option B+ was 96.8%. We enrolled 268 women initiating lifelong ART in the follow-
up. Overall, 65 (24.3%) discontinued treatment, either defined by loss to follow-up 29(44.6%) or 
actively stopped treatment 36(55.8%). Retention-in-care was 88.0% and 81.1% at 6 and 12 months, 
respectively. Discontinuation was significantly associated in multivariate analysis with small sites 
and high staff turnover [aOR 2.5 (95% CI 1.6, 3.9), p < 0.001].  At 12 months 88.6% of women 
retained in care had good treatment adherence. After adjusting for confounders, younger age, 
attending a Pentecostal church, low level of education and employment in the informal sector 
significantly predicted poor adherence.  
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Conclusion 
Twelve months retention-in-care and adherence for women retained were 81.1% and 88.6% 
respectively. Retention-in-care was lowest at small facilities with a high staff turnover while 
adherence was poor for younger, women with low level of education, attending Pentecostal 
churches and employed in the informal sector. 
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1. Introduction 
1.1 Background 
Prevention of mother-to-child transmission (PMTCT) services have been part and parcel of 
most national HIV control programmes though their implementation has varied greatly 
across countries and over time. New HIV infection among children and maternal and child 
deaths have significantly dropped in high-income countries but the milestones so far 
reached in low- and middle-income countries leave much to be desired (UNAIDS, 2014b). 
If HIV-positive pregnant women in Africa have access to quality, life-saving antiretroviral 
drugs for their health or as prophylaxis to prevent HIV transmission during pregnancy, 
delivery and breastfeeding, HIV transmission can be reduced to less than 5% (UNAIDS, 
2015; UNICEF, 2012). A randomized control trial  of pregnant and breastfeeding women 
on highly active antiretroviral therapy (HAART) in Botswana produced a rate of mother-to-
child-transmission (MTCT) monitored at 6 months after birth of 1.1% (Shapiro et al., 
2010). 
 
In 2011 the Joint United Nations Programme on HIV/AIDS (UNAIDS) launched an 
ambitious programme to eliminate new HIV infections among children while keeping their 
mothers alive (UNAIDS, 2014b). This was known as the global plan towards the elimination 
of new HIV infections among children by 2015 and keeping their mothers alive, which 
covered all low- and middle-income countries but with special focus on 22 countries with 
the highest number of pregnant women living with HIV. These countries which later on 
became known as the priority countries of the global plan are all found in sub-Saharan 
Africa but for India. More global and national commitments are needed in sub-Saharan 
African countries with over 90% of pregnant women living with HIV in need of 
comprehensive PMTCT services (UNAIDS, 2014b). 
The Global Plan over-arching goals states, “Global goal 1: Reduce the number of new HIV 
infections among children by 90% and Global goal 2: Reduce the number of AIDS-related 
maternal deaths by 50%” (UNAIDS, 2014b). 
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At the end of 2015 despite all the concerted efforts put in place by the World Health 
Organisation (WHO) in consultation with partner organisations these goals were far from 
being met (UNAIDS, 2016a).  A lot has been done to come up with the most efficacious 
treatment regimen for HIV-positive pregnant women and their babies (WHO, 2013). 
However, these efforts towards universal expansion of ART coverage with the most 
effective regimens have been constrained by limited resources. These efforts were 
progressively put in place and in 2010, the WHO recommended two PMTCT options for 
HIV-positive pregnant and breastfeeding women not eligible for lifelong ART based on 
clinical and/or immunologic criteria as follows: 
− The first option (Option A) includes maternal Zidovudine (AZT) from 14 weeks of 
pregnancy, plus single-dose Nevirapine plus Zidovudine and Lamivudine (AZT/3TC) 
during labour and delivery and one week of AZT/3TC postpartum with Nevirapine 
syrup for the infant from birth till cessation of breastfeeding.  
− The second option (Option B) introduced the use of triple ARVs (based on 
recommended first-line ART) to the mother from 14 weeks of pregnancy through 
labour, delivery and until cessation of breastfeeding. (WHO, 2010)  
By 2011, UNAIDS estimated that only 57% of HIV-infected pregnant women in low and 
middle-income countries received the WHO–recommended PMTCT regimens and that 
same year, an estimated 300,000 infants acquired HIV infection from their mothers in sub-
Saharan Africa (WHO, 2011). 
 
In 2011, the Malawian Ministry of Health, after evaluating its ARV coverage in PMTCT and 
recognising the challenges with CD4+ T-cell based testing required to implement the WHO 
recommendation, decided to adopt a pragmatic and ambitious public health approach to 
improve the low PMTCT ART coverage in Malawi known as “Option B+”(CDC, 2013). With 
Option B+ all HIV-infected pregnant and breastfeeding women are immediately initiated 
on lifelong ART, regardless of clinical stage or CD4+ T-cell count. Option B+ has come to 
eliminate the previous complex PMTCT algorithms, which relied on CD4 testing and ART 
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start and stop with each pregnancy with Option B, thus simplifying the PMTCT process, 
with expected important health and social benefits for HIV-infected women, their HIV-
exposed infants, and their HIV-uninfected sex partners (Ahmed, Kim, & Abrams, 2013; M. 
S. Cohen et al., 2011; Schouten et al., 2011). 
 
The WHO/UNAIDS recommendations of 2011 aimed at a final MTCT of 5% or less in 
breastfeeding populations and 2% or less in non-breastfeeding populations (UNAIDS, 
2014b). Reaching these objectives in the low resource countries had been daunting and 
required extra efforts and more commitment from the national governments. Many 
African countries adopted one or the other of the WHO recommendations and their 
choices were more or less driven by cost and logistics and not the efficacy of the regimen. 
It was for this reason that most of the countries including Cameroon opted for the less 
costly option A. However, it soon  became clear that this option was more complicated 
and less cost-effective in the long run (Gopalappa, Stover, Shaffer, & Mahy, 2014). In 2013 
the WHO issued the first consolidated guidelines on the use of antiretroviral drugs for 
treating and preventing HIV infection in which it recommended immediate ART for all HIV-
positive pregnant and breastfeeding women irrespective of clinical stage or CD4+ T-cell 
count (WHO, 2013). In 2016, WHO further expanded the eligibility criteria and now 
recommended test and treat for all but with special emphasis on pregnant women, 
children and key populations (WHO, 2016). 
 
Although early results from Malawi and elsewhere indicate  an important increase in ART 
initiation for the target population and cost effectiveness of Option B+ (Fasawe et al., 
2013; Gopalappa et al., 2014; VanDeusen, Paintsil, Agyarko-Poku, & Long, 2015), 
important concerns still remain on safety, ethical issues including preferences for 
treatment options, sub-optimal adherence and retention, with the possibility of increased 
postpartum transmission and HIV drug resistance development (Coutsoudis et al., 2013; 
Ngarina et al., 2014). 
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1.2 Problem Statement 
Since the launch of the Global plan by UNAIDS in 2011, the number of new HIV infections 
among children has declined by 60% between 2009 (year of baseline) and 2015 in the 21 
Global Plan priority countries compared to 13% decline between 2000 and 2008 (UNAIDS, 
2016a). This marked decline in MTCT is due to the increasing access by HIV-positive 
pregnant women to lifelong antiretroviral therapy especially with the introduction of 
Option B+ (CDC, 2013; WHO, 2013, 2016) which has been progressively implemented in 
most of the Global plan priority countries. Twelve of these countries had already achieved 
or were close to achieving full national implementation.  
 
According to the 2016 Global plan progress report, ARV coverage increased from 37% in 
2009 to 80% at the end of 2015 in the Global plan priority countries. On the other hand 
the same report showed that MTCT in 2014 was 4.7% at six weeks but this rose to 8.9% at 
the end of breastfeeding (UNAIDS, 2016a). This strongly indicated that most of the new 
infections occurred during the breastfeeding period which is more than twice the new 
infections during pregnancy, labour and delivery (Ngoma et al., 2015). This residual 
transmission is highly blamed on the reduced adherence and retention-in-care during the 
breastfeeding period due to the poor systems available to follow-up mothers postpartum 
thus leaving the infants vulnerable to acquiring infection (Ebuy, Yebyo, & Alemayehu, 
2014; Tenthani et al., 2014; Tweya et al., 2014). In a South African study looking at 
barriers to retention in Option B+ care among postpartum women, the participants 
highlighted as experienced barriers the lack of money, work conflict and negative 
treatment from health care workers as the main reasons for dropping out of care. 
However, when the women were interviewed on what they perceived as barriers for other 
women to HIV care after delivery they said the mothers care more about the baby's health 
than their own, women were irresponsible or ignorant, negative staff treatment, denial 
and lack of disclosure of status (Clouse et al., 2014).This showed how important it is to 
take the woman’s perspective into consideration when planning care for them and their 
exposed infants, especially during the postpartum period. 
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In Cameroon, a sentinel survey amongst pregnant women aged 15-49 years in 2011 put 
the HIV sero-prevalence at  7.8%,  ranging from 4.3% in the Far North Region  to 11.9% in 
the Centre Region (Billong et al., 2015). The South West Region was at 10.6% a rate much 
higher than the national prevalence of 4.3% (INS, 2011). The mother-to-child transmission 
rate still stood at 25% in 2013 (UNAIDS, 2014b). With this high HIV prevalence in 
pregnancy,  high MTCT rate and the low coverage of ART (66%) for pregnant and 
breastfeeding HIV-positive women (UNAIDS, 2015), in August 2012 and following the 
WHO programmatic updates (WHO, 2012c) the government of Cameroon decided to 
initiate a pilot project to implement Option B+ in two health districts in the country.  This 
move was also motivated by the potential advantages of Option B+ from the Malawi's 
experience which greatly simplify and integrate PMTCT and ART services avoiding stopping 
and re-starting ARVs while preventing MTCT in future pregnancies (CDC, 2013). 
 
However, there has been a significant improvement in the ARV coverage for HIV-positive 
pregnant women rising from 66% in 2014 to 82% in 2015 with a six week MTCT of 5.2% 
and a final transmission rate at 12.6% (UNAIDS, 2016b). The pilot project which is still on-
going, started in October 2013 and the roll out of Option B+ in the country became 
effective since December 2015. 
 
Moreover, the above data indicates that achieving and maintaining this  low transmission 
rate requires high coverage across the entire PMTCT cascade including; high antenatal 
attendance, high HIV testing and counselling rates, ART coverage above 90% and strong 
systems to support lifelong adherence to ART and retention-in-care for mothers 
postpartum (UNAIDS, 2015).  Considering the fact that with Option B+ healthy patients are 
going to start treatment there are concerns that these patients, especially those with 
CD4+ T-cells > 350 cell/mm3, may not be adequately retained in care and their adherence 
to treatment may be suboptimal (Grimsrud et al., 2016). 
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1.3 Rationale and significance of the study  
Cameroon with a 6-8 week MTCT rate at 5.2% and a final transmission rate at 12.6% 
(UNAIDS, 2016a) still points to the fact that many of the residual HIV infections in infants 
are still occurring during the breastfeeding period. There is thus, an urgent need to 
support pregnant and breastfeeding women so that they are retained in care and adhere 
to antiretroviral therapy throughout the risk periods of pregnancy and breastfeeding. The 
impact of both low retention-in-care and poor adherence to ART is most evident when 
one focuses at the final MTCT rates (Jean B Nachega et al., 2012; Ngoma et al., 2015). 
Following early implementation of treatment under Option B+ in Cameroon, adherence 
and retention-in-care have not been determined. Considering that adherence and 
retention-in-care following this new treatment option could be country specific and could 
vary with the approach used in measurement, we therefore decided to carry out this 
study to determine retention-in-care, adherence and treatment outcomes for HIV-positive 
pregnant and breastfeeding women initiating Option B+ in Cameroon.  
 
This study which was carried out alongside the pilot project and the eventual scale up of 
Option B+ in Cameroon was also an opportunity to better characterise the determinants 
of adherence and treatment discontinuation. To better evaluate retention-in-care and to 
properly assess adherence to lifelong ART for these women, the HIV testing and 
counselling uptake and the ART uptake of women attending the antenatal care and infant 
welfare services in the Kumba health district were first established. We measured 
adherence with a composite adherence score comprising of an indirect objective measure 
(pharmacy refill) and two indirect subjective measures (4-day patient self-report and 30-
day visual analogue scale). The results of this pioneer study will assist the national 
programme in developing strategies to achieve optimal retention-in-care and improve 
adherence, which are very important determinants of treatment success as Option B+ is 
progressively being implemented in Cameroon. 
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1.4 Objective 
The overall objective of this study was to evaluate retention-in-care and adherence among 
HIV-positive pregnant and breastfeeding women initiating lifelong antiretroviral therapy in 
the context of PMTCT Option B+ in the South West Region of Cameroon. 
1.5 Hypothesis 
Retention-in-care and adherence to lifelong ART for HIV-positive pregnant and 
breastfeeding women initiating treatment with a CD4+ T-cell count >350 cell/µL is much 
lower than for those initiating therapy for their own health i.e. with CD4+ T-cell count ≤ 
350 cell/ µL. 
Null hypothesis 
There is no observed difference in retention-in-care and adherence between HIV-positive 
pregnant and breastfeeding women initiating lifelong antiretroviral therapy with a CD4+ T-
cell count >350 cell/ µL when compared with those initiating therapy for their own health 
(CD4+ T-cell count ≤ 350 cell/ µL).  
1.6 Research Questions  
1. What is the HIV testing and counselling uptake and ART uptake in pregnant and 
breastfeeding women attending antenatal care (ANC) and infant welfare (IWC) 
services in Kumba Health District, Cameroon? 
2. What is the difference in the rate of retention-in-care on lifelong antiretroviral therapy 
for HIV-positive pregnant and breastfeeding women who initiate Option B+ with CD4+ 
T-cell count ≤ 350cell/ µL compared to those with CD4+ T-cell count >350cell/ µL at 6 
and 12 months? 
3. What is the difference in the rate of adherence to lifelong antiretroviral therapy for 
HIV-positive pregnant and breastfeeding women initiating Option B+ with CD4+ T-cell 
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count ≤ 350cell/ µL compared to those with CD4+ T-cell count >350cell/ µL at 6 and 12 
months? 
4. How does adherence measured with a composite adherence score (CAS) predict viral 
suppression in HIV-positive pregnant and breastfeeding women initiating Option B+ in 
Cameroon? 
5. What are the important predictors of suboptimal adherence in pregnant and 
breastfeeding women initiating option B+ in Cameroon and retained in care? 
6. What are the reasons for discontinuation of lifelong antiretroviral therapy in pregnant 
and breastfeeding mothers initiating Option B+ in Cameroon? 
7. What is the testing (PCR) uptake and HIV-free survival at 2 months (6-8 weeks) for 
exposed babies of women on Option B+ in Cameroon?  
8. What is the maternal mortality (all causes included) and adverse pregnancy outcomes 
(pre-term delivery, low birth weight, abortions etc.) observed with Option B+? 
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2. Review of literature 
2.1 Overview of the global HIV and AIDS epidemic 
UNAIDS estimated that at the end of 2015, a total of 36.7 million persons were living with 
HIV (PLHIV) infection worldwide, as compared with 29.1 million in 2001 with 25.8 million 
(70%) of these living in sub-Saharan Africa (UNAIDS, 2016b). Though the greatest impact 
of the HIV/AIDS epidemic with heterosexual transmission is today in sub-Saharan Africa, it 
originated in men who have sex with men (MSM) in the United States and Western 
Europe (De Cock, Jaffe, & Curran, 2012). The peculiarities of this epidemic include the 
disproportionate burden borne by females, especially in sub-Saharan Africa, where more 
than 70% of infected females reside (Simon, Ho, & Karim, 2006). In 2015, two million 
persons were newly infected and 1.2 million died a decline of 47.8% from 2005, when the 
number of AIDS deaths peaked at 2.3 million. Sixty six per cent (790,000) of the deaths 
among PLHIV in 2014 occurred in sub-Saharan Africa (UNAIDS, 2016b).  Similarly, the 
number of new infections among neonates and infants in the global plan countries has 
decreased from 270,000 in 2009 to 110,000 in 2015 as a result of improved PMTCT 
interventions (UNAIDS, 2016a). However, these global figures tend to hide a wide diversity 
amongst regions and countries. 
 
The prevalence of HIV infection among adults according to continent and country varies 
greatly with sub-Saharan Africa continuing to be the most affected continent, followed by 
Eastern Europe and the Caribbean. Nigeria is a special case among the global plan 
countries with 41,000 newly infected children in 2015, a number equivalent to the next 
eight countries of the global plan combined. Without Nigeria the remaining 20 countries 
of the global plan had a 69% reduction in new HIV infections among children by the end of  
2015 (UNAIDS, 2016a). 
 
Although all regions of the world are affected by this pandemic, southern Africa is now 
fully confirmed as the epicentre of the global HIV/AIDS epidemic. One-third of the global 
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HIV infection and about half of the world’s HIV-associated tuberculosis are found in nine 
southern Africa countries which account for less than 2% of the world’s population (De 
Cock et al., 2012). This high HIV prevalence has frequently been associated with lack of 
male circumcision and high rates of sexually transmitted infections such as HSV-2 infection 
(Bailey et al., 2007; Buvé et al., 2001; Gray et al., 2007). Even within a country, the 
prevalence of HIV infection varies widely according to region and risk group as is the case 
in Cameroon and several other countries within the sub-region (INS, 2011). As of 
December 2015, 17 million people living with HIV globally were accessing antiretroviral 
therapy, up from 15.8 million in June 2015 and 7.5 million in 2010 greatly surpassing  the 
UNAIDS target of 15 million by 2015 (UNAIDS, 2016b). In 2015 there was a dramatic 
improvement of children access  to treatment globally up from 21% to 49%, slightly 
surpassing adult treatment access which stood at 46% (UNAIDS, 2016b).  
2.2 Epidemiology of HIV infection in Cameroon  
Cameroon has an HIV prevalence of 4.3% representing one of the most affected countries 
in central Africa region (INS, 2011). Across the country the women are disproportionately 
more infected than the men (Figure 2.1) and this has contributed to the high mother-to-
child transmission rate. The main risk groups in the country include; commercial sex 
workers, men who have sex with men, truck drivers, fishermen, and military personnel 
(CNLS, 2014). The sero-prevalence amongst pregnant women aged 15-49 years is 7.8% 
and this varies greatly across the different regions (Billong et al., 2015). The ARV coverage 
for pregnant women in Cameroon rose from 36% in 2009 to 82% in 2015. This was 
accompanied by a significant drop in mother-to-child transmission with an early (6-8 
weeks) transmission rate of 5.2% and a final transmission at the end of all breastfeeding of 
12.6% dropping from 8% and 22% in 2014 respectively (UNAIDS, 2016a). It should be 
noted that since May, 2007, Cameroon instituted a free ART policy for all patients living 
with HIV and eligible for ART. This included children and pregnant and breastfeeding 
mothers. However, adherence and retention-in-care and treatment for HIV-positive 
pregnant and breastfeeding women remains a serious public health concern as most 
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women enrolled in care drop out very early leaving their infants at risk of HIV infection 
(Ngoma et al., 2015; UNAIDS, 2016a). 
 
Figure 2.1: National HIV Prevalence in Cameroon by regions and by sex (men and women          
aged 15-49 years) 
(Adopted from EDS-MICS 2011)  
The HIV prevalence in Cameroon varies greatly by region ranging from 1.2% in the 
extreme north to 7.2% in the south region (Figure 2.2). The urban areas especially the big 
cities are more affected than the rural areas (INS, 2011). 
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Figure 2.2: National HIV Prevalence in Cameroon by regions (men and women aged 15-49 
                      years) 
 (Adopted from EDS-MICS 2011). 
2.3 History of the PMTCT programme in Cameroon 
With an estimated population of 21,700,000 people living in Cameroon in 2013, 660,000 
were living with HIV. There were approximately 9,500 new HIV infections in 2014 among 
pregnant women, with only 40% of these women receiving ARV treatment or prophylaxis 
(CNLS, 2015). The Prevention of Mother-to-Child Transmission of HIV (PMTCT) programme 
in Cameroon started in its pilot phase in the year 2000 in the Centre, North-West and 
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Littoral Provinces (now regions). In 2000, the Elizabeth Glaser Pediatric AIDS Foundation 
(EGPAF) supported the first five PMTCT health facilities in Cameroon in partnership with 
the Cameroon Baptist Convention Health Services (CBCHS). It witnessed an extension in 
2002 in the West and South West regions. It gained ground from July 2003 covering the 
rest of the regions. The PMTCT programme was officially launched in 2003. The 
nationwide scale up of PMTCT services started in 2003 with all the regional and district 
hospitals and by 2006 PMTCT services were present in all health districts nationwide 
following the district approach. Single-dose Nevirapine (sdNVP) was used for the period 
2001 to 2012 though Cameroon introduced AZT combination prophylaxis in 2006 with AZT 
being initiated at 28 weeks of pregnancy, followed by sdNVP and AZT/3TC during labour 
and AZT/3TC tail for a week. This was progressively rolled out with the gradual removal of 
sdNVP. Infants received NVP syrup at birth for a week or more depending on duration of 
exposure of the mother to ARVs before pregnancy. This was guided by the 2006 PMTCT 
national guidelines.  
 
These guidelines were updated in 2011 following the WHO 2010 guidelines introducing 
Options A and B as PMTCT options. Cameroon just like most African countries opted for 
Option A whereby the pregnant women started AZT prophylaxis at 14 weeks up to 
delivery, then sdNVP with AZT/3TC during labour with an AZT/3TC tail for a week while 
those eligible for treatment were referred for triple therapy for their own health. The 
babies then received NVP prophylaxis until complete cessation of breastfeeding. In August 
2012, following the April 2012 WHO programmatic updates that recognized the potential 
advantages and the need to take into consideration the new Option B+ approach 
introduced by Malawi within a public health perspective in resource-limited settings 
(WHO, 2012 2b), Cameroon decided to adopt Option B+. However, it was not until 
October 2013 that Option B+ was piloted in the country in two health districts, Bamenda 
and Kumba of the North West and South West regions respectively with funding from 
President Emergency Plan for AIDS Relief (PEPFAR). Full scale up of Option B+ in Cameroon 
was only effective as from December, 2015 with the production of a consolidated national 
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guideline for treating and preventing HIV infection (CNLS, 2015) and a ministerial circular 
letter authorising all sites to systematically start all HIV-positive pregnant and 
breastfeeding women on tenofovir, lamivudine, efavirenz (TELE) irrespective of their 
disease clinical classification or CD4+ T-cell count.  
2.4 HIV Transmission, pathogenesis, disease progression and natural history 
2.4.1 HIV transmission  
HIV is transmitted through three main routes, namely; the sexual route, through blood 
and blood products and from mother-to-child. HIV Transmission depends on the 
infectiousness of the source person and the susceptibility of the exposed one. Infectivity 
varies during the course of illness and is not constant between individuals. Transmission of 
HIV is dependent on a large number of behavioural and biologic factors.  Some of the 
many variables that influence the probability of HIV transmission include the genetic 
background of the potential host, the size and infectiousness of the inoculum, and the 
local environment in which the exposure occurs (Dean, Carrington, & Winkler, 1996). 
Factors that result in physical disruption of the exposed mucosa, such as the use of vaginal 
desiccants or the presence of genital ulcer disease and other sexually transmitted 
infections, can enhance viral transmission (Pantaleo et al., 1998). Based on its genetic 
make-up, the HIV-1 virus which is responsible for the world’s pandemic is divided into four 
groups namely; M (main), N (new), O (outlier) and P. While HIV-2 has groups A-H. The M 
group which constitutes the major group has nine subtypes and the subtype C is dominant 
representing about 55-60%. Transmission also depends on the virus strain.  HIV-1 is more 
easily transmitted than HIV-2 which is found principally in West Africa. More than 70 
circulating recombinant forms (CRFs) have also been identified and can easily be 
transmitted. 
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2.4.1.1 Sexual transmission  
Sexual transmission occurs through the contact of genital secretions of an infected person 
with the disrupted rectal, genital, or oral mucous membranes of an uninfected person. 
The size of the inoculum and the integrity of these membranes are important determinant 
factors in sexual transmission. The risk for transmitting HIV through unprotected anal 
intercourse is greater than the risk from vaginal intercourse or oral sex (Rothenberg, 
Scarlett, del Rio, Reznik, & O'Daniels, 1998). 
2.4.1.2 Blood and blood products   
This transmission route was recognised as early as 1983 as the HIV infection was found to 
spread among intravenous drug users (IDU), recipients of blood and blood products like 
haemophiliacs and through occupational exposure in health care settings (De Cock et al., 
2012). A major risk factor for HIV infection is the sharing and reusing syringes 
contaminated with HIV-infected blood. World Health Organisation estimates that 
approximately 2.5% of all HIV infections in sub-Saharan Africa are transmitted through 
unsafe healthcare injections (WHO, 2008).  Before the advent of the HIV epidemic a  
majority of the world's population did not have access to safe blood and most HIV 
infections may have occurred through transfusion of infected blood and use of blood 
products (De Cock et al., 2012).  
2.4.1.3 Perinatal or Mother-to-child transmission (MTCT) 
More than 90% of children living with HIV got infected through mother-to-child 
transmission. The transmission of the virus from an infected mother to the child can occur 
in utero during the last weeks of pregnancy, during childbirth and through breastfeeding. 
However, most transmission occurs during labour and delivery when the baby comes in 
direct contact with maternal blood and secretions. Many factors influence vertical 
transmission varying from pregnancy, through delivery and breastfeeding. The table 
below summarises the risk factors involved in MTCT.  In the absence of any intervention 
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mother-to-child transmission ranges from 25-40% (WHO, 2006).  The most important risk 
factor that cuts across all time points is the maternal viral load. 
Table 2.1: Risk factors of Mother-to-child transmission of HIV  
Time point of HIV transmission and risk factors associated 
Pregnancy Labour and delivery Breastfeeding 
- High maternal viral load 
(new infection or 
advanced AIDS) 
- High maternal viral 
load (new infection or 
advanced AIDS) 
- High maternal viral load 
(new infection or 
advanced AIDS) 
- Sexually Transmitted 
Infections (STIs) 
- Rupture of membranes 
for more than 4 hours 
- Prolonged breastfeeding 
- Viral, bacterial, or 
parasitic placental 
infection 
- Invasive delivery 
procedures that 
increase contact with 
mother’s infected 
blood or body fluids 
(e.g. episiotomy, foetal 
scalp monitoring) 
- Prolonged labour 
- Mixed feeding, 
particularly during the 
first 6 months of life (e.g. 
food or fluids in addition 
to breast milk) 
- Poor maternal 
nutritional status 
- First infant in multiple 
birth 
- Breast abscesses, nipple 
fissures, mastitis 
- Chorioamnionitis (from 
an untreated STI or 
other infection) 
- Preterm delivery - Poor maternal nutritional 
status 
 - Low birth weight - Oral disease in the baby 
(e.g. oral thrush or sores) 
Adapted from WHO, 2006 
2.4.2 Pathogenesis 
The pathogenesis of HIV infection is a complex, multi-factorial process involving viral and 
host factors. The net degree of virus replication in vivo reflects a balance of factors that 
positively or negatively regulate virus expression.  In turn, the amount of virus replication 
appears to be intimately related to the rate of CD4+ T-cell depletion that occurs, and thus 
to the rate of disease progression. The clinical features of HIV infection vary depending on 
the stage of disease. In the acute and early stages of the disease, symptoms resulting from 
immune hyper-activation predominate. However, with the inexorable depletion of CD4+ 
T-cells that characterizes disease progression, overt cellular immunodeficiency and its 
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many complications develop (Camaur & Trono, 1996). The CD4+ T-cell count is an 
excellent long term marker of the degree of immunodeficiency and determines the 
immediate risk of opportunistic infections and other AIDS-related complications (Masur et 
al., 1989). The plasma viral load is the most valuable short term prognosticator of HIV 
infection that is currently available. Viral load not only predicts disease progression 
independent of the CD4+ T-cell count, but also actually predicts the trajectory of the CD4+  
T-cell count (Mellors et al., 1997). 
2.4.2.1 Acute Infection 
Although more than half of primary HIV infections are accompanied by symptoms, most of 
these infections are not recognized in the acute setting (T. Schacker, Collier, Hughes, Shea, 
& Corey, 1996).  The differential diagnosis of primary HIV infection is extremely broad, 
given the variable presentations associated with the syndrome and the ubiquity of the 
observed signs and symptoms. Fever, rash, pharyngitis, and lymphadenopathy are 
common during primary HIV infection, as they are in many “flulike” and “mononucleosis-
like” illnesses (Niu, Stein, & Schnittman, 1993). Myalgias, arthralgias, diarrhoea, nausea, 
vomiting, headache, hepatosplenomegaly, weight loss, thrush, and neurologic symptoms 
also may occur. Among patients who develop symptoms during primary HIV infection, the 
mean duration of symptoms is 3 weeks (Kinloch-de Loës et al., 1993). Plasma HIV RNA 
levels vary widely in primary HIV infection, from thousands to millions copies per millilitre 
(T. W. Schacker, Hughes, Shea, Coombs, & Corey, 1998). The peak level of HIV RNA (viral 
set point) may have prognostic value, and persistently high levels after 4 to 6 months add 
to the predictive power towards more rapid progression of disease (Mellors et al., 1995). 
2.4.2.2 Early-Stage Disease 
The natural history of HIV infection includes a long period of clinical latency between the 
time of primary infection and the development of symptoms indicative of advanced 
immune deficiency. In the tropics, this period has an average duration of 4 – 5 years or 
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less. Generalized lymphadenopathy and some degree of fatigue are characteristic of this 
period of clinical latency. As the CD4+ T-cell count falls below 500 cells/ µL symptoms and 
syndromes indicative of depressed cell-mediated immunity in HIV infection that are not 
AIDS defining generally begin to appear. Examples include recurrent vulvovaginal 
candidiasis, multi-dermatomal herpes zoster, pelvic inflammatory disease, oral hairy 
leukoplakia associated with Epstein-Barr virus (EBV), cervical dysplasia (usually associated 
with human papillomavirus infection), constitutional symptoms such as unexplained fever 
or diarrhoea lasting more than 1 month, idiopathic thrombocytopenic purpura, and 
peripheral neuropathy (Buehler & Berkelman, 1990).  
2.4.2.3 Late-Stage Disease - AIDS 
As the CD4+ T-cell count decreases below the level of approximately 200 cells/ µL, the loss 
of integrity of cell-mediated immune responses allows ubiquitous environmental 
organisms with limited virulence (e.g., Pneumocystis jiroveci and Mycobacterium avium) to 
become life-threatening pathogens. Conditions indicative of severely depressed cell 
mediated immunity due to HIV infection constitute the CDC surveillance case definition of 
AIDS (Buehler & Berkelman, 1990).  
2.4.2.4 Determinants of Disease Progression 
Several host and virologic factors determine the extremely variable rates of disease 
progression that are observed among HIV-infected individuals (Dalmau et al., 2009). A 
small percentage of HIV-infected individuals experience no evidence of disease 
progression over a prolonged period. These long-term non-progressors provide clues 
regarding factors associated with disease progression. The ability of certain HLA molecules 
to present immune-dominant viral epitopes efficiently to generate cell-mediated immune 
responses may explain an association with slow disease progression. Conversely, other 
HLA haplotypes (HLA-B35) may preclude an effective cell-mediated antiviral response and 
may therefore be associated with more rapid disease progression (Carrington et al., 1999). 
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Genetic polymorphisms in the HIV co-receptors and their ligands may also significantly 
affect the course of HIV disease progression. Individuals who are homozygous for a 32- 
base pair deleting  mutation within the CCR5 gene (CCR5-Δ32) are afforded a high degree 
of protection against HIV infection, whereas HIV-infected heterozygotes are partially 
protected against disease progression (Carter & Saunders, 2007). Genetic polymorphisms 
in the chemokine–chemokine receptor axis genes represent only one of 15 possible 
mechanisms responsible for some resistance to HIV infection or delayed disease 
progression. Levels of CCR5 expression exhibit considerable inter-individual variability and 
these levels correlate with infectivity of cells with R5 strains of HIV in vitro (Wu et al., 
1997). Studies of long-term non-progressors and exposed-uninfected individuals indicate 
important roles for CTL, CD8+T-cell suppressor factors, CD4+ T-helper responses, 
neutralizing antibody responses, and mucosal humoral immune responses in protecting 
against HIV infection or disease progression (Pantaleo et al., 1994).  
 
2.4.3 Natural course of HIV infection 
The natural course of any disease describes the evolution of the disease in an individual 
from the moment of infection to death without any medical intervention. This has been 
possible to observe directly in HIV infected patients since the first therapies were only 
available about seven years after the first cases were described in 1981. Figure 2.3 shows 
the natural course of HIV infection, how the immune system interacts with the virus until 
the late disease and how this can affect disease progression and HIV transmission in the 
population. Viral replication is highest at early infection and at the late stage of the 
disease.   This is particularly important in mother-to-child transmission as a woman who 
gets infected during the pregnancy runs a higher risk of MTCT than a woman who got 
pregnant with her HIV infection (WHO, 2006). 
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Figure 2.3: The course of HIV-1 infection defined by the level of viral replication  
(Adopted from Simon et al., 2006): 
Plasma viraemia (top) and dynamic changes of the CD4+ T-lymphocyte compartments 
(bottom). Primary infection is characterised by high plasma viraemia (red line, top), low 
CD4 cells (green line, bottom), and absence of HIV-1 specific antibodies (orange line, 
bottom). Viraemia drops as cytotoxic CD8+ T-lymphocytes (CTL) develop (blue line, bottom) 
and an individual viral-load set point is reached during chronic infection. Viral set points 
differ greatly among individuals (e.g., red dotted line, top) and predict disease progression. 
Viral diversity increases throughout the disease (closed circles, top). The risk of 
transmission is highest in the first weeks when viraemia peaks (closed circles, top) and 
during late disease. GALT=gut-associated lymphoid tissues. (p.27) 
PhD thesis,  PASCAL NJI ATANGA  21 
 
2.5 Management of HIV infection  
In 2014, WHO and UNAIDS set an ambitious treatment target to help end the AIDS 
epidemic by 2030.  The 90-90-90 target by 2020 i.e. 90% of people living with HIV should 
know their status, 90% of people with diagnosed HIV infection should be initiated and 
maintained on a sustained ARV treatment and 90% of those on ARV treatment should 
attain viral suppression will guide the AIDS agenda beyond 2015 (UNAIDS, 2014a). This 
target is far from being met especially in sub-Saharan African countries where a lot of 
people still do not know their HIV status and access to viral load monitoring is still limited 
(Piot et al., 2015).  
With the recent adoption of test and treat for all, WHO has proposed a general package 
for care for people living with HIV in order to reduce new HIV transmission, to prevent 
illness and to improve the quality of life of PLHIV. This care package could vary depending 
on the epidemic type, population affected, prevalence of co-infections, other 
comorbidities and general health conditions (WHO, 2016). In this care package that cuts 
across the continuum of care, WHO recommends a package of 13 prevention 
interventions that will help guide the management of adults and adolescents living with 
HIV in resources constrained settings: “(1) Psychosocial counselling and support; (2) 
disclosure and partner notification; (3) cotrimoxazole prophylaxis (CTX); (4) TB counselling, 
screening and preventive therapy; (5) preventing common fungal infections; (6) treatment 
of STIs and supporting reproductive health needs, including prevention of and screening 
for cervical cancer; (7) preventing malaria (CTX, bed-nets and particularly preventing 
malaria among pregnant women); (8) the use of vaccines for the prevention of 
pneumococcal disease, influenza, hepatitis B and yellow fever; (9) provision of adequate 
nutrition; (10) family planning services; (11) prevention of mother-to-child HIV 
transmission; (12) needle and syringe programmes for people who inject drugs;  and (13) 
water, sanitation and hygiene”. This comprehensive package of care will require enough 
human and material resources to be implemented at all service delivery points in resource 
limited settings.   
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2.5.1 Diagnosis 
Since lentiviral infections are persistent, antiviral antibodies are present throughout the 
lifetime of the infected host. Detection of antiviral antibodies is thus the most widely used 
method for determining the presence of viral infection. However, diagnosis could also be 
done using antigens, or both, and many commercial kits are now available. The serological 
test that are readily available today can be done on plasma, serum, whole blood or saliva 
by health care workers with little laboratory expertise following minimal training with 
same day results possible (Simon et al., 2006). Serological diagnosis of HIV entails the use 
of first and second-generation assays of HIV antibodies, which employ whole virus lysate 
and recombinant proteins respectively. Third generation assays employ a mixture of  
recombinant antigens from the core (gag),  pol  (polymerase) and env (envelope) products 
of HIV-1 and HIV-2, and it is most widely used (McMillan  et al.,  2002).  
Serologic test are limited in that they cannot diagnose early infection and are not suitable 
for diagnosis of HIV infection in children younger than 18 months. The use of dried blood 
spot (DBS) specimen has resolved some of the challenges associated with transportation 
and storage of samples needed for virological assessments especially for early infant 
diagnosis and more recently for viral load testing (WHO, 2013). 
It is recommended that  for surveillance studies in settings with HIV prevalence ≤ 10%, 
two testing strategies should be used (WHO, 2013). Most national programmes have 
developed testing algorithms for HIV antibody testing for disease surveillance, diagnosis or 
blood transfusion identifying the different tests to be used depending on the test 
sensitivity and specificity. Most of the testing algorithms perform serial testing with the 
first test being highly sensitive and the second test being highly specific (CNLS, 2015). 
2.5.2 Clinical staging 
Measurement of CD4+ T-cells and viraemia is required for disease staging and patient 
follow-up especially during treatment with ARVs. Treatment failure and therapeutic drug 
monitoring for treatment success should be monitored with plasma viral load. CD4+ T-
cells count measures the degree of immunodeficiency and is, therefore, used to assess the 
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stage of infection. CD4+ T-cell counts together with clinical manifestations (e.g., 
occurrence of opportunistic infections) are key criteria for HIV disease classification.  
The clinical staging and case definition of HIV for resource-constrained settings were 
developed by the WHO in 1990 and revised in 2007 (WHO, 2007). Clinical stages are 
categorized as 1 through 4, progressing from primary HIV infection to advanced HIV/AIDS 
based on specific clinical conditions or symptoms (Table 2.2). Even with the coming in of 
test and treat for all, disease staging should follow a confirmed HIV infection prior to 
initiation of treatment as this will serve as a baseline for better follow-up of the patient 
while on ART.  
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Table 2.2: WHO Clinical Staging of HIV/AIDS for Adults and Adolescents  
WHO clinical stage Clinical conditions or symptoms 
Primary HIV infection Asymptomatic 
Acute retroviral syndrome 
Clinical Stage 1 Asymptomatic 
Persistent generalized lymphadenopathy 
Clinical Stage 2 Moderate unexplained weight loss (<10% of presumed or measured 
body weight) 
Recurrent respiratory infections (sinusitis, tonsillitis, otitis media, and 
pharyngitis) 
Herpes zoster 
Angular cheilitis 
Recurrent oral ulceration 
Papular pruritic eruptions 
 Seborrheic dermatitis 
Fungal nail infections 
Clinical stage 3 Unexplained severe weight loss (>10% of presumed or measured body 
weight) 
Unexplained chronic diarrhoea for >1 month 
Unexplained persistent fever for >1 month (>37.6°C, intermittent or 
constant) 
Persistent oral candidiasis (thrush) 
Oral hairy leukoplakia 
Pulmonary tuberculosis (current) 
Severe presumed bacterial infections (e.g., pneumonia, empyema, 
pyomyositis, bone or joint infection, meningitis, bacteraemia) 
Acute necrotizing ulcerative stomatitis, gingivitis, or periodontitis 
Unexplained anaemia (haemoglobin <8 g/dL) 
Neutropenia (neutrophils <500 cells/mL) 
Chronic thrombocytopenia (platelets <50,000 cells/mL) 
Clinical Stage 4 HIV wasting syndrome, 
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Pneumocystis jirovecii pneumonia (PCP) 
Recurrent severe bacterial pneumonia 
Chronic herpes simplex infection (oro-labial, genital, or anorectal site 
for >1 month or visceral herpes at any site) 
Oesophageal candidiasis (or candidiasis of trachea, bronchi, or lungs) 
Extrapulmonary tuberculosis 
Kaposi sarcoma 
Cytomegalovirus infection (retinitis or infection of other organs) 
Central nervous system toxoplasmosis 
HIV encephalopathy 
Cryptococcosis, extrapulmonary (including meningitis) 
Disseminated nontuberculosis mycobacteria infection 
Progressive multifocal leukoencephalopathy 
Candida of the trachea, bronchi, or lungs 
Chronic cryptosporidiosis (with diarrhoea) 
Chronic isosporiasis 
Cryptococcosis, extrapulmonary (including meningitis) 
Disseminated mycosis (e.g., histoplasmosis, coccidioidomycosis, 
penicilliosis) 
Recurrent nontyphoidal Salmonella bacteraemia 
Lymphoma (cerebral or B-cell non-Hodgkin) 
Invasive cervical carcinoma 
Atypical disseminated leishmaniasis 
Symptomatic HIV-associated nephropathy 
Symptomatic HIV-associated cardiomyopathy 
Reactivation of American trypanosomiasis (meningoencephalitis or 
myocarditis) 
Adopted from WHO, 2007 
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2.5.3 Management of opportunistic infections 
When the immune system becomes severely damaged following HIV infection the patients 
start developing opportunistic infections. The risk of contracting some opportunistic 
infections varies in line with the degree of destruction of the immune system. Mycotic skin 
and mucous membrane infections or herpes zoster develop as a result of minor damage. 
In Africa most patients will also develop tuberculosis (TB) at this stage even though TB 
usually develops in patients with late stage disease. TB is the most common opportunistic 
infection and the major cause of mortality in people living with HIV (Simon et al., 2006; 
WHO, 2007). Most TB infections in these patients are due to endogenous reactivation but 
the risk of acquiring a new infection after infection with HIV is twenty times higher than in 
HIV-negative individuals and extra-pulmonary forms of TB are more prevalent. Other 
opportunistic diseases such as Kaposi sarcoma, pneumocystis jiroveci pneumonia, cerebral 
toxoplasmosis, cytomegalovirus virus retinitis or lymphomas are diagnosed when the 
immune system is severely compromised, usually when the CD4+ T-cell count is less than 
200 cells per microliter.  
Without treatment most of these opportunistic infections will further damage the 
immune system resulting in very high viral load and increase the risk of mother-to-child 
transmission. Adequately diagnosing and treating a major opportunistic infection takes 
priority over antiretroviral therapy but optimal timing of antiretroviral therapy in all 
patients and especially in pregnant women where ART remains an emergency is very 
important (WHO, 2016). Co-trimoxazole prophylaxis is recommended for adults (including 
pregnant women) with severe or advanced HIV clinical disease (WHO stage 3 or 4) and/or 
with a CD4+ T-cell counts < 350 cells/mL unlike in children and adolescents whereby 
prophylaxis should be provided irrespective of clinical or immunologic condition (WHO, 
2016). 
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2.5.4 Antiretroviral therapy 
Antiretroviral therapy (ART) refers to the use of a combination of three or more 
antiretroviral drugs for treating HIV infection. Lifelong ART is now recommended for all 
patients diagnosed with HIV irrespective of the immunological or clinical condition of the 
patient (WHO, 2016). However, test and treat does not exclude adequate adherence 
counselling and assessment of patients for treatment preparedness or willingness to 
initiate ART. Of nearly 22,000 women who started ART under option B+ in Malawi 17% 
were lost to follow-up six months after ART initiation. Loss to follow-up was highest 
among women who began ART at large clinics on the day they were diagnosed with HIV 
(Tenthani et al., 2014). This further emphasizes the need to have the client adequately 
prepared and mindful of the implications of lifelong ART. This decision might be 
overwhelming and complex to take immediately after HIV diagnosis. World Health 
Organisation suggest that it is good practice to make a lot of efforts to reduce the time 
between HIV diagnosis and ART initiation based on the assessment of the person’s 
readiness to start? If the person decides not to start ART immediately, counselling should 
continue and the advantages of early initiation adequately explained to the client and ART 
can be proposed at subsequent clinical visits (WHO, 2016). WHO further call on national 
programmes, to strike the balance between starting pregnant and breastfeeding women 
without delay and ensuring that women are adequately prepared, have accepted lifelong 
ART and have access to support systems, including peer support, to promote treatment 
adherence and retention-in-care (WHO, 2016). 
2.5.4.1 Classification of antiretroviral drugs 
Antiretroviral (ARV) drugs are broadly classified by the phase of the retrovirus life cycle 
that the drug inhibits (Figure 2.4). 
− Entry inhibitors (or fusion inhibitors);  Examples are Maraviroc and enfuvirtide. 
− CCR5 receptor antagonists. Most strains of HIV use the CCR5 receptors as ligands 
to attach to T-cells receptors.  
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− Nucleoside reverse transcriptase inhibitors (NRTI) and nucleotide reverse 
transcriptase inhibitors (NtRTI). Examples include zidovudine (AZT), stavudine 
(d4T), lamivudine (3TC), emtricitabine (FTC), didanosine (ddl), abacavir (ABC) and 
tenofovir (TDF). 
− Non-Nucleoside reverse transcriptase inhibitors (NNRTI). Examples include 
nevirapine (NVP) and efavirenz (EFV). 
− Protease inhibitors (PIs). Examples include saquinavir (SQV), indinavir (IDV), 
Lopinavir (LPv) and nelfinavir (NFV). 
− Integrase inhibitors inhibit the enzyme integrase, Example,raltegravir. 
− Maturation inhibitors 
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Figure 2. 4: Different classes of antiretroviral drugs and their point of action along the  
  lifecycle of HIV infection 
 (www.frontiersin.org, Retrieved 29th July, 2016). 
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2.5.4.2 Antiretroviral drugs and regimens used in PMTCT 
Antiretroviral use in pregnancy has changed considerably overtime and most of the 
regimen selection procedures have been driven by fear of the safety for the infant while 
providing optimal efficacy to reduce mother-to-child transmission. Prevention-of-mother-
to-child programmes started by offering short course ARV or single doses of ARV drugs to 
the mother and her infant in the first few days of life. There was a major shift in 2003 and 
later on updated in 2006 when the WHO guidelines recommended, “pregnant women 
living with HIV be assessed for treatment eligibility and those considered eligible should 
be offered lifelong combination ART for their own health, while those who were not 
eligible should receive short courses of ARV for PMTCT”. These eligibility criteria have 
changed overtime with a lot of improvement in the PMTCT treatment options (WHO, 
2006).  
In 2010 WHO adopted Options A and B as PMTCT options, this was later on revised in 
2012 with impelling evidence from Malawi who started an ambitious public health 
approach which they called Option B+ whereby all pregnant and breastfeeding women 
were immediately put on treatment following HIV diagnosis irrespective of their clinical or 
immunological status. In 2013 the first WHO consolidated guidelines was published 
recommending Option B+ as the preferred PMTCT option for all pregnant and 
breastfeeding mothers (WHO, 2010, 2012c).  
Option B+ has been seen to have the highest impact in settings with high HIV prevalence, 
high fertility and long duration of breastfeeding.  Universal ART for all pregnant and 
breastfeeding women would reduce the incidence of HIV and prevent HIV transmission in 
both current and future pregnancies (WHO, 2014). The table below summarize these 
PMTCT options that were adopted in the WHO 2013 consolidated guidelines. 
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Table 2.3: Programme options for ART for PMTCT     
National PMTCT 
programme option 
Pregnant and breastfeeding women 
with HIV 
HIV-exposed infants 
Use lifelong ART for all 
pregnant and 
breastfeeding women 
(“Option B+”) 
Regardless of WHO clinical stage or 
CDC4 cell count 
Breastfeeding Replacement 
feeding 
Initiate ART and maintain after delivery 
and cessation of breastfeeding 
6 weeks of 
infant 
prophylaxis 
with once-daily 
NVP 
4-6 weeks of 
infant 
prophylaxis with 
once-daily NVP 
(or twice-daily 
AZT) 
Use lifelong ART only 
for pregnant and 
breastfeeding women 
eligible for treatment 
(“Option B”) 
Eligible for 
treatment a 
Not eligible for 
treatment a 
Initiate ART and 
maintain after 
delivery and 
cessation of 
breastfeeding b  
Initiate ART and 
stop after delivery 
and cessation of 
breastfeeding  b c 
Adapted from WHO, 2013 
Table legend 
a CD4 count ≤ 500cells/mm3 or clinical stage 3 or 4 disease at the time of ART initiation or in 
accordance with national guidelines. 
b Patients who develop clinical or laboratory criteria indicating failure of ART during pregnancy or 
the breastfeeding should be assessed for 2nd line treatment. 
c In case of breastfeeding stop ART one week after cessation of breastfeeding. In case of 
replacement feeding stop ART after delivery. 
Later on in 2015 with the growing evidence of the importance for treating all patients 
living with HIV regardless of CD4+ T-cell count or WHO clinical staging, PMTCT has 
gradually moved away from the aforementioned options to lifelong ART treatment for all 
pregnant and breastfeeding women living with HIV. This is the current recommendation in 
the WHO 2016 consolidated guidelines. Cohen and colleagues in the HPTN 052 
randomized controlled trial showed that ART is highly effective at preventing the 
heterosexual transmission of HIV if viral suppression is achieved and maintained (Cohen et 
al., 2015).  
One very important potential benefit of universal ART for all is that it normalizes HIV 
treatment in addition to prioritising pregnant and breastfeeding women thus reducing the 
likelihood of women dropping out of care on or before the end of the transmission risk 
period. Overall, the health benefits of universal ART for pregnant and breastfeeding 
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women outweigh potential harm, but women should not be coerced to start treatment 
unless they are ready to do so. However, a right based  approach can offer women the 
opportunity to make informed decisions thus can result in better acceptability and 
improved health outcomes (WHO, 2016). 
2.5.5 Combination HIV prevention 
HIV prevention programmes today are centred around combination HIV prevention as 
current evidence shows that no single, stand-alone HIV prevention intervention offers the 
most appropriate results. It is unlikely that a single deployed intervention, even a vaccine 
(Vermund, 1998) will halt or even reverse the epidemic. However, a growing number of 
behavioral, structural and biomedical (Bailey et al., 2007; Cohen et al., 2015; Gray et al., 
2007; Halperin et al., 2011; Millett, Flores, Marks, Reed, & Herbst, 2008; Wilson & 
Halperin, 2008) HIV prevention strategies appear promising in providing some protection 
against infection. WHO reiterates that combination prevention programmes use a mix of 
biomedical, behavioural and structural interventions to meet the current HIV prevention 
needs of particular individuals and communities so as to have the greatest possible impact 
on reducing new infections (WHO, 2016). Some authors have compared combination 
prevention to combination ART: ‘Combination ART reduces HIV replication by attacking 
the virus at multiple points of its life cycle, leading to multiple therapeutic targets for 
treatment, and yielding dramatic clinical benefits. Similarly, combination HIV prevention is 
likely to be most effective when different points in the “transmission cycle” are impeded, 
combining strategies to reduce infectiousness of HIV-positive persons with strategies that 
reduce HIV susceptibility in the uninfected’ (Cremin et al., 2013). Synergistic effects are 
therefore obtained when combination prevention strategies are used.  
 
Proven interventions adopted from WHO, 2016 guidelines to be included in a combination 
HIV prevention programme includes: 
− Condoms both male and female and condom compatible lubricants 
− Treatment as prevention (early ART for infected patients) 
− Pre-exposure prophylaxis (PrEP) 
PhD thesis,  PASCAL NJI ATANGA  33 
 
− Post-exposure prophylaxis (PEP) 
− Voluntary male medical circumcision 
− Needles and syringe substitution for injection drug users 
− Opioid substitution therapy for injection drug users 
− Blood transfusion safety 
− Targeted information and education 
− Structural and supportive interventions. 
 
It is important to focus on high impact strategies but too much emphasis on a particular 
preventive intervention may just be sending out an erroneous message to the population. 
For example male circumcision is only partly preventive and to be effective it must be 
combined with other measures like condom use, otherwise some men and women will 
understand if circumcised then unprotected sex is risk-free (Merson et al., 2008). The 
other major challenge with HIV prevention is the difficulty of scaling up some behavioural 
strategies. An intervention like partner reduction (Wilson & Halperin, 2008) though 
important in generalised epidemics, but it is not a clearly defined intervention like blood 
transfusion that can be easily scaled up. The “know your epidemic” approach (Wilson & 
Halperin, 2008) involves understanding determinants of local HIV prevalence and 
incidence to identify population targets with the highest rate of recent HIV infections, and 
to maximize the prevention benefits achieved. However, the need to know one’s epidemic 
should not impedes action, if local epidemiologic data are not good enough for better 
decision making (Kurth, Celum, Baeten, Vermund, & Wasserheit, 2011). 
Different settings and populations will require different combinations of interventions. 
The best HIV prevention impact comes from offering a package of interventions carefully 
selected to suit the epidemic setting and the population. 
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2.6 Retention-in-care and treatment 
Following HIV diagnosis, prompt engagement to care and subsequent retention-in-care is 
imperative to allow access to treatment, requiring uninterrupted receipt and excellent 
adherence to achieve and sustain an undetectable plasma viral load (VL) (Fox & Rosen, 
2010; Rosen & Fox, 2011). Recognising the clinical and programmatic importance of 
retention-in-care, there is yet no standard measure for retention-in-care. Comparatively 
to linkage to care which is a dichotomous event, measuring retention is more complex as 
it includes multiple visits, scheduled at varying time intervals, and occurring across time 
(Mugavero et al., 2012). 
In 2011 in its meeting on "Retention in HIV programmes: Defining the challenges and 
identifying solutions", WHO attempted defining retention in HIV care as “the continuous 
engagement from diagnosis in a package of prevention, treatment, support and care 
services”. However, there was no common consensus as with the definitions of LTFU and 
adherence to care. Retention-in-care was defined from the moment of initial engagement 
in care, when a person with HIV is successfully linked to services, to assessment for 
eligibility, initiation on ART and retention in lifelong ART care (WHO, 2012b). Retention 
just like adherence is critical to reduce HIV-related morbidity and mortality, reduce the 
incidence of new infections in children and adults, and reduce development of ART drug 
resistance. In the context of Option B+ in which the client is initiated on treatment as an 
emergency and as such needs to be progressively and adequately prepared for lifelong 
therapy retention-in-care is thus critical. Implicit to the concept of retention-in-care is the 
sense of continuity and receipt of care at relevant time points. Early drop outs from 
treatment will seriously affect the outcome of the client and increase the risk of morbidity 
and mortality in the mother but also the risk of MTCT of HIV.  
World Health Organisation divides the continuum of care into four steps, thereby defining 
points at which patient attrition occurs. This division is very essential to identify points on 
the continuum of care where programmes need to reinforce strategies to reduce LTFU 
and subsequently improve retention in care. It  is noteworthy that the highest rates of 
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LTFU occur between testing and enrollment (Tayler-Smith et al., 2010) and up to 80% of 
patients diagnosed with HIV infection may be LTFU between testing and initiation of ART 
(Rosen & Fox, 2011). This is summarized in Figure 2.5. 
 
Figure 2.5: The 4 steps along the continuum of HIV care and treatment  
(Adopted from WHO, 2012). 
“Patient loss may occur at all 4 steps along this continuum. Step 1 – HIV testing to enrolment into 
care services; Step 2 – enrolment in care to ART eligibility (may be very short if person has WHO 
clinical stage 3 or 4 or a low CD4, or may be years for someone with a high CD4 count); Step 3 – 
eligibility to initiation of ART; Step 4 -initiation to lifelong ART”. (WHO, 2012b) 
With the  incremental expansion of ART eligibility to include all pregnant women and 
discordant couples irrespective of CD4+ T-cell count, raising the T-CD4+ cell eligibility 
threshold to less than 500cells/ µL and other co-morbidities like TB and hepatitis B and C  
(Delva et al., 2012; WHO, 2013), the continuum of care will progressively be shortened 
and the several points of LTFU are expected to reduce. In 2016, WHO has endorsed test 
and treat for all thus normalizing HIV treatment but also removing all the steps that were 
initially required to get a patient eligible before initiating ART treatment (WHO, 2016). 
Adequately assessing retention in care will depend so much on the definition of lost to 
follow-up and disengagement from care. Unfortunately there is little consensus on this 
PhD thesis,  PASCAL NJI ATANGA  36 
 
and we still find varying definitions of LTFU in the literature. WHO defines LTFU on ART as 
"patients receiving ART and not seen at the clinic, or pharmacy, 90 days after the date of 
their last missed appointment or last missed drug pick-up and who are not known to have 
transferred out or died" (WHO, 2012b). However, in a systematic review of 111 countries 
Chi et al. concluded that a universal definition of LTFU of 180 days produced the least 
misclassification (Chi et al., 2011). Even though WHO has proposed a definition for 
retention-in-care there are still a lot variations as to how retention has been defined and 
measured with no particular gold standard (Mugavero et al., 2012). In a study defining and 
analysing retention in care among pregnant and breastfeeding women, Rollins and 
colleagues comment, “Equating attendance of HIV-infected mothers clinic at 12-month 
postpartum with full retention in PMTCT over this period fails to capture patterns of 
attendance and care received by mothers and children and risk introducing error and bias. 
Thus providing only an aggregate rate of attendance as a proxy for retention in care fails 
to identify gaps in health services where interventions to improve retention along the 
PMTCT cascade are most needed”. These authors are thus emphasising that failing to 
capture missed visits, or inconsistent clinic attendance falter the continuity aspect of 
retention-in-care. They therefore, proposed a framework for defining retention-in-care 
(Table 2.5) which takes into account the number of scheduled clinic visits and the 
attendance rate (N. C. Rollins et al., 2014). The INtegrating and Scaling-up PMTCT through 
Implementation REsearch (INSPIRE) initiative aimed at evaluating interventions to improve 
retention in care among pregnant and lactating women also used varied definition of 
retention. These projects that were carried out in three countries also used different 
definitions of retention-in-care each on its part trying to integrate attendance at a given 
point in time with some elements to elucidate the pattern of attendance to capture 
continuity (Mangwiro et al., 2014; N. Rollins et al., 2014; N. C. Rollins et al., 2014).  
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Table 2.4: Framework for Defining Retention-in-care 
Term  Definition  Comment 
Attendance 
(assessed at a single point) 
Attends clinic at stated 
time point ± 2 week 
Equates with programmatic 
definition of retention-in care. 
Need to standardize breadth of 
window around time point. This 
would be reported as a stand-
alone estimate, separate from 
retention-in-care 
Retention-in-care, for 
example, assessed at 12-
month postpartum 
  
− Full Attends at stated time, 
for example, 12 month 
(±2 week) and at least 
80% of scheduled visits. 
The proportions of follow-up 
visits that constitute full or 
partial retention-in-care should 
be standardized and should 
reflect a meaningful high or 
mid-range of continuity of care. 
Consensus is needed for the 
thresholds of the proportion of 
scheduled visit to be attended. 
− Partial Attends at stated time, 
for example, 12 month 
(±2 week) but for only 
30%–80% of scheduled 
visits 
Could also consider if woman 
does not attend at stated time 
but does attend the prior 
scheduled visit and more than 
half of other scheduled visits 
Not retained in care or 
failed 
Attends,30% of 
scheduled visits 
 
LTFU Status/whereabouts not  
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known at the end of the 
study period 
Death Woman confirmed to 
have died at any time 
after enrolment 
 
Adopted from Rollins et al., 2014 
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2.7 Adherence to HIV and AIDS care and treatment 
Adherence to ART for HIV infection is important for plasma viral load suppression. This is 
key to treatment success as it reduces both morbidity and mortality but most especially 
improves the quality of life and reduces HIV drug resistance development (Bangsberg, 
2008; Mills et al., 2006; Paterson et al., 2000). With an effective treatment regimen that 
fully suppresses viral replication, non-adherence is the only most important factor that 
leads to viral resistance. Unfortunately, health care workers are incapable of easily 
identifying patients who may or may not easily adhere to their treatment. It is therefore, 
important to perform formal adherence measurements in the course of treatment to 
provide an opportunity to identify who may require adherence support measures and 
take appropriate action. 
Many tools have been developed over the years to assess HAART adherence.  However, 
there is yet no gold standard on how to measure adherence (Oyugi et al., 2004). An ideal 
adherence measurement tool should be reliable, valid and logistically practical, without 
constraining either the participant or staff administering it (Simoni et al., 2006). However, 
in clinical settings, some authors think measures must be efficient, practical, and 
inexpensive, and precision may be less important than accurately identifying patients in 
need of interventions (Berg & Arnsten, 2006). The available methods have been 
categorized as either direct or indirect (L. Miller & R. Hays, 2000; Turner, 2002). Direct 
methods such as biological assays of active drug, metabolite or other markers in blood, 
urine, or other body fluids and directly observed treatment (DOT) confirms active drug 
ingestion. Indirect methods, which do not measure the level of the drug in the individual, 
include self-reports and visual analogue scale (VAS), clinician assessment, medical chart 
reviews, clinic attendance, pill counts (PC- announced and un announced), pharmacy refill 
records, medication or drug possession ratio, electronic drug monitoring (EDM) or 
medication even monitoring system (MEMS) and therapeutic impact such as HIV-1 viral 
load (VL), CD4+ T lymphocyte count, WHO staging of disease progression and mortality.  
Other publications go ahead to categorize the indirect methods into subjective and 
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objective depending on how the information is obtained (L. G. Miller & R. D. Hays, 2000; 
Paterson, Potoski, & Capitano, 2002; Steel, Nwokike, & Joshi, 2007). One of the most 
widely used indirect subjective measures of adherence is the self-report due to its 
practicality. These assessment methods have their advantages and disadvantages. In all, 
antiretroviral adherence is crucially important in resource limited settings where second 
line medication options are limited and third line regimens are virtually non-existent. Sub-
optimal adherence must be timely and accurately identified and managed prior to the 
development of drug resistance. 
2.7.1 Direct methods of adherence measures 
2.7.1.1 Therapeutic drug monitoring 
Therapeutic drug monitoring (TDM) which involves measuring drug levels in the blood 
may fail to account for the variability of pharmacokinetic factors of medications and 
individuals and may be invasive. Their routine use in monitoring adherence for patients on 
treatment is limited to the protease inhibitor classes. In nucleoside reverse transcriptase 
inhibitors (NRTI), blood levels may not directly infer levels inside HIV-infected cells. This 
approach is expensive limiting its use in developing countries. Biomarkers can be used to 
monitor adherence by adding secondary non-toxic medicines to indicate the presence of 
the primary medicine initially taken. Factors other than adherence may affect drug levels, 
such as drug-drug interactions and diet. Also, serum drug levels only reflect adherence 
over the past 24 hours, and patients who are aware of a planned visit may ingest 
medication in anticipation of the test.  
2.7.1.2. Directly observed therapy 
Direct observed therapy (DOT) method which has been widely used in TB treatment 
allows health care workers or supervisors directly administer medicines to patients. This 
method confirms adherence since the health care worker or supervisor observes the 
patient taking the medicine. Direct observation is objective and practical only in single-
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dose therapy, intermittent administration and hospitalized patients. DOT has been used 
with success in settings of great privation like prisons with inmates (Farmer et al., 2001). 
Unfortunately its application in HIV may be limited since it is a chronic condition and 
treatment is life-long. Some see it as stigmatising, paternalistic and deprives the patient of 
his privacy. Due to cost and lack of the necessary logistics, direct methods of adherence 
assessment are seldom used in low resource settings. 
2.7.2 Indirect methods of adherence measures 
2.7.2.1 Self-report adherence 
This is one of the most widely used methods of adherence assessment for patients on 
HAART both in clinical and research settings. This personal interview or written 
questionnaire has many advantages among which are, low cost and flexibility in terms of 
mode of administration (Wagner & Miller, 2004). Additionally, the specificity of self-report 
measures is high, .i.e. patients' acknowledgement of non-adherence is generally credible 
(Bangsberg, Hecht, Clague, et al., 2001). With its flexibility, barriers and facilitators to 
adherence can be assessed with self-reports but are completely inaccessible with other 
adherence assessment methodologies (Simoni et al., 2006). In a meta-analysis the authors 
found that despite significant study heterogeneity, the pooled association between self-
reported ART adherence and patient vireamia was statistically significant, adjusted OR = 
2.31, 95% CI = 1.99, 2.68 (Nieuwkerk & Oort, 2005). However, Nieuwkerk and Oort in their 
study commented, “Patients early in their experience with HAART are more inclined to 
complete self-reports carefully. With time, patients may become accustomed to the self-
report instruments and may learn that there are advantages to reporting higher 
adherence which makes it easier for them to complete the forms and could spare time 
that may be allocated to counselling about adherence based on their responses” 
(Nieuwkerk & Oort, 2005). 
On the contrary, self-report is susceptible to recall bias, inaccurate memory and 
potentially to social desirability bias. Self-report may produce estimates of adherence that 
are 10-20% higher than those from electronic drug monitoring (Arnsten et al., 2001; 
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Wagner & Miller, 2004). Overestimated adherence rates can result in patient 
misclassification and may lead to inaccurate targeting of adherence-improving 
interventions or delays in addressing adherence problems. Some guidelines now exit to 
greatly reduce social desirability bias. Using self-administered questionnaire with open-
ended and forced choice items, introducing the topic with a preamble acknowledging the 
challenges and difficulty of attaining perfect adherence, wording items in such a way that 
non-adherence is presented as expected and accepted (Vinten, 1998; Wagner & Miller, 
2004).  
Reasons for non-adherence are then assessed specifying a time frame, focusing on recent 
behaviour, aiding recall when possible, attaching reports to salient events, embedding 
threatening with non-threatening items, using authority to justify and normalize the 
behaviour and ending with a reliability check of the accuracy of responses (L. Miller & R. 
Hays, 2000). Patients do report more accurately over briefer time periods.  The recall 
period for self-report assessments varies with different studies ranging from three to 
seven days (Golin et al., 2002; Reynolds et al., 2007; Steel et al., 2007; Wagner & Miller, 
2004). However, the consensus is to have shorter recall periods to reduce recall bias 
though some authors hold that the seven day recall or having questions about adherence 
over the weekends were very important since adherence is problematic during weekends 
(Reynolds et al., 2007). Interestingly, despite the shortcomings of self-reported adherence 
it remains one of the most widely used adherence measure both in clinical and research 
settings. 
2.7.2.2 Linear Visual Analogue Scale (VAS) 
VAS is an instrument that tries to measure a characteristic or attitude that is believed to 
range across a continuum of values and cannot be easily measured directly. It is also 
considered as a subjective assessment of adherence which assesses adherence over a 
month prior to the assessment date. To measure adherence, the patient is asked to place 
a mark somewhere along a line from 0 to 10 that best describes their adherence to the 
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prescribed ARVs. VAS is a simple tool for uncovering adherence and has the potential for 
use for both clinical and research purposes in resource-constrained settings. The reliability 
and validity of the VAS has been demonstrated (Giordano, Guzman, Clark, Charlebois, & 
Bangsberg, 2004). This instrument which has been used to assess medication adherence  
for several years is based on the work of Walsh (Walsh, Mandalia, & Gazzard, 2002). 
2.7.2.3 Pharmacy Adherence Measures  
Pharmacy refill or pill pickup records for measuring adherence to ART, pharmacy 
adherence measures (PAMs), are adherence estimates calculated using dates of 
prescription refills and/or pill counts performed during routine clinic visits (Bangsberg, 
2008). PAMs which are not affected by recall or social desirability bias are objective and 
may be calculated from information routinely available in medical and pharmacy records 
(Meyer et al., 2011; Simoni et al., 2006).  
 
In a systematic review of studies assessing adherence using PAMS the authors found that 
studies conducted in Low and middle income countries (LMICs) generally assessed ART-
naive populations receiving nonnucleoside reverse transcriptase inhibitor (NNRTI) 
containing regimens and demonstrated that PAMs were predictive of either virological 
failure or virological suppression (Meyer et al., 2011). PAMs may however, overestimate 
actual pill taking if individuals discard or share pills and, therefore, estimate maximum 
possible adherence.  
 
On the other hand the most commonly used PAMs in clinical settings are pill count (PC) 
and patients may find this unacceptably intrusive or paternalistic which may eventually 
harm the physician-patient relationship. The patient may also forget to bring their pill 
bottles to scheduled visits and it is time consuming. Despite these limitations, in settings 
with limited routine viral load monitoring, PAMs can play an important role in monitoring 
individual and population-level adherence to ART. The table below identifies three broad 
categories of PAMs. 
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Table 2.5: Pharmacy-Based Adherence Measure (PAMs) Categories 
PAM category Definition Formulae 
Medication or drug 
possession ratio 
(MPR) 
Measures the amount of time an 
individual is in possession of >1 ARV or 
prescriptions for the ARVs as a 
proportion of the time between 2 ARV 
pick-ups or prescriptions 
Number of days ARV prescribed or 
dispensed/number of days in the 
interval. 
Pill count Measures the quantity of ARV pills an 
individual has used between 2 ARV 
pickups as a proportion of the number 
of pills dispensed or as a proportion of 
time between pick-ups 
1. (Number of ARV pills dispensed – 
number of ARV pills 
returned)/number of ARV pills 
dispensed. 
2. (Number of days ARV pills 
dispensed – number of days ARV 
pills returned)/ number of days in 
the interval. 
Pill pickup Measures whether an individual picks 
up all or a majority of their prescribed 
ARVs and expresses the adherence 
estimate in a dichotomous fashion 
(some measures require that ARVs be 
picked up on or before the date the 
previous ARV supply finishes). 
1. Where ‘‘Adherent’’ = (ARV refills 
picked up/ARV refills prescribed)> 
predefined value 
2. Where ‘‘Adherent’’= (ARV refills 
picked up prior to previous refill 
finishing/ARV refills prescribed)> 
predefined value. 
 Adopted from Meyer et al., 2011 
2. 7.2.4 Medication Event Monitoring System (MEMS) 
Medication Event Monitoring System (MEMS) is considered by many to be the current state-
of-the art method of assessing adherence, as its results strongly predict clinical outcome 
(Arnsten et al., 2001; Bangsberg, Hecht, Charlebois, Chesney, & Moss, 2001). Although 
commonly employed, the electronic medication monitor has several potential limitations. 
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It requires that (1) all medications are stored in the electronic monitor container, (2) only 
the correct numbers of pills are taken out with each dose, (3) the container is only opened 
during dosing, and (4) the monitor is closed after each dose (Bangsberg, Hecht, Charlebois, 
et al., 2001). Unfortunately, though readily available and has been used for decades in 
developed countries, MEMS caps are not easily available in developing countries except in 
few research settings (Steel et al., 2007). 
 
2.7.3 Composite Adherence Measure (CAM) 
Several studies have shown that pharmacy refill and pill count adherences are lower than 
self-reported adherence and higher than adherence measured by MEMS (Arnsten et al., 
2001; Chalker et al., 2010; Liu et al., 2001). It is therefore, evident that no single method 
provides the gold standard needed to assess adherence. Employing a technique that 
combines information from several measures will thus reduce the error that would be 
introduced by using a single method. (Berg & Arnsten, 2006; Steel et al., 2007). 
 
The first composite adherence score was produced and used in 2001 by Lui et al. The 
composite score produced method was higher than EDM and lower than both pill counts 
and self-reports. Compared to each individual adherence measure that made up this 
composite score, the score was the most highly correlated with virologic response (Liu et 
al., 2001). In another review the authors thought this might not be routinely required in 
clinical settings where viral loads and other biological markers are often readily available and 
funds for additional assessments are limited (Simoni et al., 2006).   In a summary measure of 
adherence using the 4 items of the AIDS Clinical Trial Group (ACTG) Adherence 
Questionnaire, the scored adherence was found to be strongly associated with plasma HIV 
RNA outcome and compared favourably with adherence estimates based on discrete 
medication event monitoring systems (MEMS) indices (Reynolds et al., 2007). A validated 
multi-method tool has been in used in South Africa to monitor patient adherence in 
routine clinical care (Steel et al., 2007). Several authors are unanimous on the use of a 
multiple adherence measures to better predict treatment outcome but there is yet no 
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consensus on how many measures to combine, how best to combine them and even how 
many time points to include. (Bangsberg, 2008). This could continue to vary overtime and 
with different settings as treatment protocols changes towards single dose regimens in 
order to improve adherence.  
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3. Methods 
3.1 Study design and settings 
This prospective cohort study investigated linkage to care including the uptake of HIV test 
and counselling (HTC) procedures, uptake of maternal ART, and retention to HIV care and 
treatment after initiation of Option B+ procedures with a targeted follow-up period of at 
least 12 months. The study was carried out in five health facilities (District Hospital 
Kumba, Presbyterian General Hospital Kumba, Kumba Town Urban Integrated Health 
Centre, Catholic Health Center Fiango and Ntam Integrated Health Centre Kumba) located 
within the Kumba Health District, South West Region, Cameroon, offering antenatal care 
(ANC), postnatal and infant welfare services. These facilities were selected based on high 
coverage, specifically receiving well over 90% of the pregnant women seeking ANC in the 
health district. Facilities were classified as large if they had a median monthly first ANC 
attendance of over 70 women and as small if the median monthly first ANC uptake was 
below 70 women.  
These sites were among the ten sites that were selected to pilot Option B+ in this region 
with its staff being the first to be trained in Option B+ procedures and task shifting in the 
country.  At the initiation of the pilot project staffs from all five health facilities were 
trained on Option B+ procedures and task shifting and the numbers of trained staff varied 
according to the volume of the site. Between 4 and 8 staff were trained per site. Task 
shifting allows midwives and nurses to prescribe and follow-up HIV-positive clients on 
ART. Facilities that lost more than 75% of their trained PMTCT staff within 6 months of the 
pilot project were classified as having a high staff turnover and those who lost between 
50% and 75% of their trained PMTCT staff were considered as having a moderate staff 
turnover. 
Alongside the clinical staff, a team of peer educators were trained to implement 
community follow-up of clients and especially tracking cases of women missing their clinic 
appointments and getting them back to care. 
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3.2 Description of the PMTCT programme in the South West Region, Cameroon 
The PMTCT programme in the South West Region, Cameroon has been scaled up to cover 
the entire region since October 2011 by the Cameroon Baptist Convention Health Services 
(CBCHS) with funds from the United States’ President's Emergency Plan For AIDS Relief 
(PEPFAR) working together with the Ministry of Public Health (MOPH), the Elizabeth 
Glaser Paediatric AIDS Foundation (EGPAF) and the Clinton Health Access Initiative (CHAI) 
through its HIV-Free South West project. Kumba health district in the South West was the 
first in the country alongside the Bamenda health district in the North West to pilot option 
B+ in the country since October of 2013. Option B+ is now fully rolled out in the region 
since the beginning of 2016. 
In the South West region, the pilot project took place in 10 health facilities of the Kumba 
health district including public, private and faith based health facilities. Within the PMTCT 
programme the MOPH provides most of the HIV test kits and the PEPFAR project provides 
just a buffer stock to avoid any stock outs.  MOPH equally provides the ARVs required by 
the HIV-positive pregnant and breastfeeding mothers and their exposed babies alongside 
cotrimoxazole prophylaxis for the mother-baby pairs. CHAI on its part provides the region 
for this project with point of care (POC) CD4 machines. It has also strengthened laboratory 
capacity in collection and shipment of dried blood spot (DBS) samples for PCR testing from 
the entire region to the reference Laboratory in Mutengene. This was further reinforced in 
2013 with the introduction of the ‘bikers for health'. These are bike riders trained and 
provided with bikes to transport DBS samples and PMTCT reports from the various health 
facilities to the health district and in turn transport PMTCT commodities and utilities back 
to the health facilities. This has gone a long way to overcome one of the main challenges 
which is poor road infrastructure in the region. CHAI has also put in place at all district 
health services PCR SMS printers which are connected by internet to the reference 
laboratory to reduce the turnaround time in PCR result delivery. Another PEPFAR 
implementing partner also based in the region, Global Health Systems Solutions (GHSS) 
which is working very closely with the US Centre for Disease Control and Prevention (CDC) 
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is monitoring the main laboratories in the region for quality assurance in HIV rapid testing. 
In 2013, their services were expanded to include the 10 health facility laboratories that 
were included in the pilot project. This observational study was therefore carried out 
within this programmatic set up so that the results will reflect a real programme situation 
and will therefore help to inform policies in the rolled out of Option B+ in Cameroon. 
3.3 Study population 
The study population included all pregnant and breastfeeding women attending ANC, 
postnatal or infant welfare clinic (IWC) services for their first visit from the five selected 
health facilities of the Kumba Health District.  
3. 3.1 Inclusion criteria 
- HIV-positive pregnant and breastfeeding women irrespective of age attending ANC, 
postnatal and infant welfare clinics (IWC) in 5 selected health facilities of the Kumba 
health district who gave their informed consent. However, adolescents and women 
under 21 years needed parental or guardian consent.   
- Resident in the Kumba Health District and available for follow-up for the planned study 
duration. 
3.3.2 Exclusion criteria 
- HIV-positive pregnant and breastfeeding women already on highly active antiretroviral 
therapy, 
- Resident outside the Kumba health district area. This was to give all study participants 
the same opportunity to be followed up by peer educators through home visits and 
phone calls, 
- Women who had any history of a medical or psychiatric disorder by interview and 
physical examination according to standard practices, which in the judgment of the 
treating physician or attending midwife/nurse, would interfere with or serve as a 
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contraindication to adherence to the study protocol or ability to give informed 
consent. 
3.4 Ethical considerations 
Ethical clearance for this study was obtained from the Institutional Review Board (IRB) of 
the University of Buea and administrative authorization from the Regional Delegation of 
Public Health of the South West Region to carry out research in the health district and 
health facilities within the region. Ethical waiver was obtained from the ethical review 
board of the Medical Research School of the Ludwig-Maximilians-Universität München.  
The attending midwife or designee ensured that before a pregnant or breastfeeding  
woman agreed to participate in the study, she understood its purpose, the procedure and 
any risks or benefits associated with the study by either providing her with the study 
information sheet or reading out and explaining the information sheet in case participant 
could not read or write.  The woman was given enough time to study the informed 
consent form and had a chance to ask questions about the study. All women were 
informed that participation in the study was voluntary.  A woman was free to decide not 
to take part in the study or stop being in the study at any time without it having any 
adverse consequences on the medical care she received at the moment or in the future or 
that of her baby or other relations.  Individual written consents were obtained from each 
woman. Women who could not read had the consent form read to them by a study staff 
and they could give their informed consent by using their thumb prints. The informed 
consent carried only initials and the study code of the study participant for reasons of 
confidentiality. A copy of the signed informed consent form was then given to the woman 
to keep. All the tests required were routine in the study area for the follow-up of HIV 
positive-pregnant or breastfeeding women and their baby-pairs and the follow-up of 
PLHIV on antiretroviral therapy. However, the viral load at 12 months or soon after on ART 
was paid for entirely by the project. ARV treatment or cotrimoxazole prophylaxis for all 
study participants in this study was given free of charge. 
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3.5 Sample size consideration 
To calculate the sample size we considered the primary hypothesis of a lower adherence 
in pregnant and breastfeeding women placed on life-long ART with a CD4+ T-cell count 
>350 cell/µL when compared to women who were placed on life-long ART based on 
CD4+T-cell count ≤350 cells/µL. Adherence to lifelong ART for PLHIV in Cameroon since 
the advent of free antiretroviral therapy in May, 2007 ranged between 80% and 95% 
(Mahy et al., 2011; Mbopi-Kéou, Djomassi, & Monebenimp, 2012; Mbuagbaw et al., 2012) 
for patients eligible for HAART. In a systematic review of adherence during and after 
pregnancy the authors estimated the pooled adherence in women with CD4+ T-cell count 
<350 cell/µL at 72% (Jean B Nachega et al., 2012). However, because we could not find 
any reference to adherence in women beginning ARVs at a CD4+ T-cell counts 
>350cells/µL we hypothesized that adherence in these women would be 15% lower. A 
study of ANC HIV-positive attendees  in two semi-urban clinics in Buea, Cameroon 
predominantly (82.4%) had CD4+ T-cell >350 cells/µL (Takow et al., 2013). We thus 
assumed that two-thirds of our patients would have CD4+ T-cell >350 cells/µL and one-
third a CD4+ T-cell ≤350 cells/µL. The sample size was calculated using the G*-Power 3 
calculator (Faul, Erdfelder, Lang, & Buchner, 2007) considering a power of 80% at a 
significance level of 5% to be able to identify this difference. We obtained a total 
minimum sample size of 236 with an attrition rate of 10% (CD4+ T-cell count >350 cells/µL 
=157 and CD4+ T-cell count ≤350 cells/µL = 79). 
3.6 Study procedures 
Women at first ANC registration visits underwent a group education session including HIV 
counselling messages, followed by ‘opt-out’ provider-initiated HIV antibody rapid testing, 
and individual post-test counselling for women assessed with an unknown HIV status. In 
the delivery room women with unknown HIV status were also counselled and provided 
HIV testing. HIV testing and counselling uptake was assessed and defined as the 
proportion of pregnant women received at first ANC or in the labour room who got newly 
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tested for HIV of all women seen with an unknown HIV status from the five participating 
sites. 
Psychosocial and adherence support for women diagnosed HIV-positive were provided on 
ART initiation and followed-up by peer educators (PE). New ANC and labour cases were 
registered, an ARV follow-up card was opened for every HIV-positive woman initiating 
lifelong ART, and tracing information was documented by PE following individual consent. 
In addition, HIV infected breastfeeding mothers who were not yet on ART were recruited 
at the health facility’s affiliated infant welfare clinics (IWC). 
 
HIV-infected pregnant or breastfeeding women were started on lifelong ART  based on a 
fixed dose combination of tenofovir, lamivudine and efavirenz (TELE) regardless of their 
clinical or immunological status in accordance with WHO and national guidelines (CNLS, 
2015; WHO, 2013). Those who had initially started Option A were switched to Option B+ if 
they consented. In women with new HIV diagnosis, ART was initiated on the same day of 
diagnosis. To determine ART uptake we included all consenting pregnant and 
breastfeeding women from the five sites newly diagnosed HIV-positive including those 
who switched from option A to B+ and those known HIV-positive but were not yet on ART.  
Baseline socio-demographics, clinical and laboratory information were collected on study 
specific questionnaires and case report forms. Participants were then seen monthly for 
follow-up during ARV dispensing visits managed at ANC and IWC post-delivery by trained 
nurses or midwives.  Clinic refill appointments were programmed during the first two 
weeks of the month. After the third week, clients who had not shown up for their 
scheduled visit were considered having missed their appointment and the PE immediately 
embarked on their search if consent to be traced by phone calls and /or home visits was 
available. Tracing outcomes were recorded as: (i) lost to follow up (LTFU) if the search 
went on for more than 90 days and the client was not reachable; (ii) transferred to 
another ART clinic if the client was reachable and confirmed to receive ART from another 
clinic and this was then verified by the PE; (iii) stopped treatment if the client was 
reachable but decided not to come back to care, in which case the reasons for stopping 
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treatment were noted; (iv) death. Women who were LTFU and those who had stopped 
treatment were considered having discontinued treatment. The date of treatment 
discontinuation was set at the date of the last missed appointment. Patients who were 
dead or transferred out were censored at the date of death or transfer. All women were 
followed up from ART initiation to the date of outcome of interest or censored at the 31st 
December 2015 date of database closure for women enrolled in the study.  
All HIV exposed infants (HEI) after deliveries were enrolled and an HEI follow-up card was 
opened for them. During routine IWC, HEI were routinely followed up and DBS samples 
for DNA- PCR collected at 6-8 weeks. These samples were then transported to the district 
health service by 'bikers for health' for onward shipment to the reference laboratory. If 
HEIs were negative on the first PCR and remained asymptomatic they got an HIV antibody 
rapid test at 9 months and only children with positive antibody test at 9 months were 
eligible for a second PCR or else they had a confirmatory HIV antibody rapid test at 18 
months after cessation of all breastfeeding. All the HEI were systematically put on 
cotrimoxazole prophylaxis as from 6 weeks of age until confirmation of their HIV status. 
For those whose PCR results came back positive, they were maintained on cotrimoxazole 
prophylaxis and were immediately transferred to the nearby HIV/AIDS management unit 
for initiation and follow-up on ART treatment. Babies born in the cohort were followed up 
till May 31st 2016 date of database closure for the exposed infants and those with 
complete 18 months follow up had their HIV antibody rapid test done. 
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3.7 Definition of outcomes 
3.7.1 Primary outcomes 
Our primary outcomes were retention-in-care and adherence to lifelong ART at 6 and 12 
months post ART initiation.  
3.7.1.1 Retention in care 
Retention-in-care was defined as the proportion of women who had started on lifelong 
Option B+ ART and attended clinic visits at month 6 or 12, or any stated time prior to 
database closure or who were transferred out but known to continue ART following 
tracing information. Since we assessed treatment discontinuation i.e. LTFU or intentionally 
stopping ART and then used this as a continuous function to estimate retention in care in 
a time series analysis we are confident that our estimates will capture the continuity 
aspect of retention in care. 
3.7.1.2 ART adherence 
Adherence was measured using three measures which were then combined into a 
composite adherence score and the overall adherence at 6 or 12 months was defined as 
the composite scores at 6 or 12 months. Previous studies have shown that available 
adherence measures have limitations, raising questions about how best to measure drug 
taking behaviour (Liu et al., 2001; Steel et al., 2007); consequently we decided to use a 
composite adherence score to more objectively measure adherence in our cohort. 
3.7.2 Secondary outcomes 
Our secondary outcomes included HIV testing and counselling (HTC) uptake, ART uptake, 
treatment discontinuation, reasons for discontinuation, risk factors of treatment 
discontinuation, 12 months virologic suppression, HIV free survival at 6-8  weeks and 
maternal mortality and adverse pregnancy outcomes (abortions, still birth, preterm 
delivery and low birth weight). Maternal viral load was measured at 12 months post ART 
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initiation or soon after. The overall early HIV-free survival in the exposed babies was 
assessed at 6-8 weeks using the DNA-PCR following national guidelines and outcome 
compared to mothers composite adherence score at 12 months. For children who 
attained 18 months in the cohort prior to database closure for exposed babies, a final 
HIV-free survival was assessed using an HIV antibody rapid test after cessation of all 
breastfeeding. We collected additional data on service delivery, staffing, facility type and 
size.  
3.7.2.1 HIV testing and counselling uptake 
HTC uptake was defined as the proportion of pregnant women received at first ANC or in 
the labour room who got newly tested for HIV of all women assessed with an unknown 
HIV status. 
3.7.2.2 ART uptake 
ART uptake was defined as the proportion of HIV infected pregnant or breastfeeding 
women who were ART-naïve or on previous Option A starting on lifelong ART for Option 
B+. 
3.7.2.3 Treatment discontinuation rate 
This was defined in this study as the proportion of women LTFU without any further 
information following 90 days tracing procedures and those who had intentionally 
stopped treatment of all women initiating lifelong ART. The date of treatment 
discontinuation was set at the date of the last missed appointment. 
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3.7.2.4 Virologic suppression 
A patient’s viral load was considered suppressed if the plasma viral load collected at least 
12 months after ART initiation was less than 1,000 copies/ µL on a single measurement 
(CNLS, 2015; WHO, 2016). 
3.7.2.5 Abortions 
Abortions were defined as any pregnancy terminating on or before 28 weeks of gestation. 
3.7.2.6 Preterm delivery  
Any baby born alive before 37 weeks of pregnancy are completed was considered preterm 
(WHO, 2012a). 
3.7.2.7 Low birth weight 
Low birth weight was defined as any baby born alive with a body weight less than 2,500 
grams irrespective of the gestational age. 
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3.8 Data collection procedure  
A rigorous process was put in place to assure the quality of the data collected through 
trainings, supervision and continuous mentoring of the data collection staff monthly on 
the field by the principal investigator. 
3.8.1 Training and pretesting of questionnaire 
We found that at all participating health facilities, the same staff were involved in 
antenatal care, delivery room, postnatal care and infant welfare services. The number of 
staff varied from one facility to the other depending on the work load.  We thus selected 
between two and four staff from each participating facility and they were given a two days 
training. A total of 15 nurses and midwives were trained on the objectives of the study, 
the data collection tools and interviewing techniques especially in assessing adherence. 
The second day of the training was dedicated to the piloting of the questionnaire and this 
culminated in a debriefing session at the end of the day. The questionnaire was pre-tested 
with 15 participants at the district hospital Kumba with staff taking turns to administer the 
different sections of the questionnaire. Analysis of the piloted questionnaires and the 
inputs from the debriefing session led to some modifications before the production of the 
final version of the questionnaire and study forms.  
3.8.2 Monthly supervision 
The principal investigator (PI) carried out monthly supervisory visits to all the five facilities 
to ensure the quality of data collection and to also motivate the staff. At each visit the PI 
cross-checked all filled visits to assure completeness and accuracy and also updated his 
monitoring spread sheet. With the help of this spread sheet the PI was able by phone calls 
to remind a facility as to when a patient’s appointment was due. This greatly helped to 
assure accuracy and data completeness. 
3.9 Construction, use and interpretation of the composite adherence score (CAS) 
Steel and colleagues combined four items in the composite score they validated for South 
Africa including; Pill count, Pill instruction test, Visual analogue scale and a self-report. 
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This was necessary to account for the different types of pills that constituted the dose and 
the number of times medication had to be taken a day (Steel et al., 2007). In this study all 
women who initiated Option B+ in the pilot project were all on a single fixed dose 
combination therapy with tenofovir, lamivudine and efavirenz (TELE). We opted to use a 
composite adherence measure to reduce the errors associated with using a single 
adherence measuring tool. Since we had just a single once daily regimen which did not 
have any food or water restrictions, we did not need the pill instruction test and our 
adherence score was simply built on three elements including; Pill pick up from pharmacy 
refill records, a self-report questionnaire with 4 items and a 30-day visual analogue scale. 
We included the pharmacy refill record because till date in Cameroon ARVs are sourced 
and distributed by only one body through approved ARV treatment centres and Option B+ 
sites free of charge.  We did not also include the pill count because of its demonstrated 
shortcomings (Berg & Arnsten, 2006).  
 
Adherence was first estimated by each measure and classified into three categories as 
high, moderate and low before finally combing the results of the three measures into the 
CAS.  
Six months after initiation of lifelong ART, the pharmacy refill records for each woman in 
care were reviewed by the study staff and the total refills documented using the ART 
cohort register. This was double-checked by cross-checking with the woman’s personal 
clinic record and the peer educator’s appointment log book to rule out any missing 
information resulting from incomplete filling of the ART register. Adherence was then 
estimated as follows; 
− if the woman had picked up all her refills for six months she was scored as highly 
adherent, 
− if she had missed one refill she was scored as moderately adherent and 
− if she had missed more than one refill her adherence was scored as poor. 
A face-to-face 4-day self-report questionnaire was then administered at the sixth month 
visit. The questions were usually prefaced by normalizing language in order to reduce 
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social desirability bias (Vinten, 1998; Wagner & Miller, 2004). The normalizing language 
we used was adopted from Steel and colleagues who developed and tested a multi-
method tool in South Africa (Steel et al., 2007). This was piloted and adapted to our 
setting before use. The version we used read thus: 
“I understand that most people taking antiretroviral medication (anti-HIV drugs) find it 
very difficult to take their medication regularly and may miss some doses. So I will not be 
surprised if you have had this happen to you. It is important for me to understand how you 
are really doing with your medicine. Don’t worry about telling me if you don’t always take 
all your doses. I need to know what is really happening, not what you think I want to hear". 
 
The interviewer then administered the four closed ended questions formulated such that 
right answer should be a no to avoid participants giving the spontaneous answer of ‘yes’ 
to save face when found in front of service providers.  The table below has the four 
closed-ended questions that were used to evaluate self-reported adherence. 
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Table 3.1: The four self-report questions 
   
Self-reported adherence 
1  Do you sometimes find it difficult to remember to take your medicine? 0=No,   1=Yes 
2 When you feel better, do you sometimes stop taking your medicine? 0=No,   1=Yes 
3  Thinking back over the past 4 days, have you missed any of your doses? 0=No,   1=Yes 
4  Sometimes if you feel worse when you take the medicine, do you stop 
taking it? 
0=No,   1=Yes 
(Adapted from Steel et al., 2007) 
Adherence in this case referred to the week before the interview took place. Self-reported 
adherence was then estimated as follows; 
− if the woman responded no to all four questions she was scored as highly adherent 
− if she responded yes to one question she was scored as moderately adherent and  
− if she responded yes to two or more questions her adherence was scored as poor.  
The last aspect of the adherence evaluation was done using the linear visual analogue 
scale (VAS) to evaluate one month adherence. This was always prefaced by normalising 
language as was the case in self-report above. The woman was then presented with the 
visual analogue scale on an enlarged plasticised chart with a pen and providing her with 
the following explanation. 
"Now I would like to ask you to estimate how much of your prescribed ARV you took in the 
last month. A mark at the left end where there is a number zero (0) means you had taken 
no medications. A mark in the middle where you see the number five (5) means you had 
taken about half of your medications and a mark on the right end where you can see the 
number ten (10) means you had taken every single dose of your medications. Please put a 
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mark on this line somewhere between 0 and 10 to describe your best guess about how 
much of your prescribed medication you took in the last month". 
The woman was then expected to put a mark along the scale as shown on the diagram 
below. 
 
Figure 3.1: Visual Analogue Scale. 
The above figure is based on the work of Walsh, 0% means the client has taken no drug, 50% 
means the client has taken about half of his/her drug, and 100% means the client has taken every 
single dose of his/her drug (Walsh et al., 2002). 
 
The midwife then transformed her best guess into a percentage and put in the score box 
beside. Adherence in this case referred to the month before the interview took place. 
Adherence was then estimated as follows; 
− if the woman scored 90% or above her adherence was high 
− if she scored between 70% and 90% her adherence was scored as moderate and 
− if she scored below 70% her adherence was scored poor.  
Since all our respondents used the whole numbers to score themselves all adherence 
rates were estimated as percentages of the whole numbers thus making the above a 
discrete rather than a continuous scale. 
The results from the three different assessment measures were then transcribed and 
combined into a composite score table by the coders and the composite adherence score 
interpreted as explained below. Scores of adherence ranged between 1 and 3 such that 
3=high (perfect adherence), 2 = moderate adherence and 1= poor (non-adherence).  
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Table 3.2: Interpreting the composite adherence score (CAS)   
Adherence measure SCORE 
Pharmacy Refill Had 6 refills (3) Missed 1 refill (2) Missed 2 or more refills (1) 
Self-Report No to all questions (3) Yes to 1 question (2) Yes to 2 or more questions (1) 
VAS 90%  or more (3) 70 & 80% (2) Less than 70% (1) 
Overall Adherence High Moderate Low 
(Adapted from Steel et al., 2007) 
Instead of just interpreting the composite adherence score by reading down the columns 
and across the table from left to right as Steel and colleagues did in South Africa (Steel et 
al., 2007), we used the sum of all possible combinations that could occur to determine 
CAS. However, if all the results appeared in the same column then the overall adherence 
was taken as that of that column. But this was not always the case in many situations as 
for the same woman her scores could spread across all adherence categories. Table 3.3 
shows how all the different possible combination of scores were combined to come up 
with the final composite adherence score of each patient.  
Table 3.3: All possible combinations of the three adherence measures of the CAS 
Adherence tool Score 
Medication refill 3 3 3 3 3 2 3 2 2 1 
Self-Report 3 3 3 2 2 2 1 2 1 1 
VAS 3 2 1 2 1 2 1 1 1 1 
Total score 9 8 7 7 6 6 5 5 4 3 
CAS High Moderate low 
 
Considering the fact that most studies have shown that moderate to high adherence is 
adequate for virological suppression with new treatment regimens (Bangsberg, 2006; 
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Kitahata et al., 2004) and given the results of the viral suppression at 12 months for our 
study participants we further regrouped the adherence into two categories such that high 
and moderate adherence was reported as good adherence and low reported as poor 
adherence. This was then used to dichotomise the adherence measure to determine the 
predictors of adherence in our cohort. 
3.10 Viral load 
3.10.1 Viral load sample collection, processing and transportation 
Once a study participant attained one year or soon after on antiretroviral therapy a whole 
blood sample was collected for viral load. For each eligible participant, venous blood (10 
ml) was collected into 10ml ethylenediamine-tetra-acetate (EDTA) vaccutainer tube by a 
trained qualified phlebotomist. The sample was immediately centrifuged and 2 ml of 
plasma aliquoted into properly labelled cryovials and stored at -20 degrees at the District 
Hospital Laboratory Kumba. Samples were always collected in duplicates to compensate 
for possible manipulation errors.   
The samples were then transported at the end of each week in an appropriate cold box to 
Buea. While in Buea, the samples were stored at -80 degrees at the Laboratory for 
Emerging Infectious Diseases of the Faculty of Science of the University of Buea. The 
samples were finally transported in a dry shipper with liquid nitrogen to the Chantal Biya 
International Research Centre (CIRCB), Yaoundé for viral load analysis. Before transporting 
the samples, the reference laboratory was informed in advance and staff kept on standby 
to receive the samples on arrival. 
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3.10.2 Sample analysis and interpretation 
Plasma viral load was determined using the automated HIV-RNA Abbott Real Time HIV-1 
m2000™ System which is made up of Abbott m2000sp (RNA extraction) and Abbott 
m2000rt systems (Abbott Molecular Inc. Des Plaines, Illinois, USA) according to 
manufacturer’s instructions. The Abbott RealTime HIV-1 assay is an invitro reverse 
transcription-polymerase chain reaction (RT-PCR) assay for the quantification of Human 
Immunodeficiency Virus type 1 (HIV-1) on the automated m2000 System in human plasma 
from HIV-1 infected individuals over the range of 40 to 10,000,000 copies/µL. The upper 
limit of quantification (ULQ) for the Abbott Real Time HIV-1 assay was 10million copies/µL, 
and the lower limit of quantification (LLQ) was equivalent to the lower limit of detection 
(LOD) i.e. 40 copies/µL for the 0.6 µL sample volume procedure. Viral load values <40 
copies/µL were considered undetectable. According to the 2016 WHO guidelines, 
adequate viral response is defined as viral load <1000 copies/µL (WHO, 2016). However, 
between 40-999 copies/µL this can be explained by a blip (intermittent low-level 
viraemia). Two persistent viral loads of ≥1000 copies/µL after ≥6 months of ART after 
adequate adherence enhancement defines virologic failure and the patient should be 
considered for switching to a second line regimen. The Abbott RealTime HIV-1 assay is 
intended for use in conjunction with clinical presentation and other laboratory markers 
for disease prognosis and for use as an aid in assessing viral response to antiretroviral 
treatment as measured by changes in plasma HIV-1 RNA levels. The Abbott Real Time HIV-
1 assay uses the automated extraction and detection m2000 system platform. This fully 
automated system has a reporting capacity of 93 patient results per an 8-h day and has 
been fully validated against other real time assays.  
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3.11 Statistical Analysis 
Data were collected on study specific questionnaires and case report forms, entered into 
an Excel spread sheet and corrected for inconsistencies before extraction for analysis. 
Data were analysed using the IBM Statistical Package for Social Sciences (version 19, IBM 
SPSS Inc., Chicago IL, USA). For retention in care, descriptive statistics were reported for 
the baseline characteristics based on the retention status of the study participants. In a 
time to event analysis, observation time began from the date of ART initiation and ended 
at either, treatment discontinuation (stop treatment or lost to follow-up), transferred out, 
death or censored at the date of May 31, 2016 date of database closure. The Kaplan–
Meier methods were used to assess treatment discontinuation and estimate retention-in-
care at 6 and 12 months post-ART initiation and beyond. Cox proportional hazards model 
was used to compare different predictors of retention-in-care. Odds ratios (OR) and 95% 
confidence intervals (CI) that assessed the likelihood that study participants of specific 
demographic characteristics as well as in specific facility type would discontinue treatment 
or adhere to treatment were generated using the generalized estimating equation within 
the generalized linear model that accounted for potential correlation with clusters within 
facilities. Variables with marginal association (p < 0.100) and those proven to predict 
retention-in-care and adherence on lifelong ART were included in the multivariate 
analyses.  Spearman correlation was used to compare the different adherence measures 
and to compare adherence at 6 and 12 months after ART initiation. Unadjusted odd ratios 
(OR) and adjusted OR were reported, including the 95% confidence intervals and an alpha 
level of <0.05 was used to define significance. 
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4. Results 
4.1 Baseline characteristics, uptake of HTC and ART  
Between October 2013 and December 2014, a total of 5,966 pregnant or breastfeeding 
women were attended to and assessed for HIV status at ANC/IWC of the five health 
facilities of the Kumba Health District. A total of 5,813 (97.4%) with an unknown HIV 
status received HIV testing and counselling (HTC) as applicable. One hundred and nineteen 
(2.0%) women were already on ART and excluded from the study, while 30 (0.5%) others 
had initiated Option A and 4 (0.1%) were known positive but were not yet on treatment. 
HTC uptake was 98.5% and 251 women were newly diagnosed HIV-positive giving a 
prevalence of 4.4%. Reasons why 90 (2.6%) women did not receive HTC were not 
assessed. In total, 285 pregnant and breastfeeding women who were either newly HIV 
diagnosed, ART naïve or previously receiving Option A regimen were eligible for Option 
B+. Of those 276 women were started on lifelong ART and 9 actively rejected ART 
initiation with a resultant ART uptake of 96.8%. Overall, 268 (94.0%) women initiating 
lifelong ART following Option B+ guidelines were included into the study, 8 (2.8%) women 
were not included as they were coming from other districts (Figure 4.1).  
 
On inclusion, study participants were interviewed on their last menstrual period (LMP) at 
ANC initiation irrespective of their pregnancy status; 18 (6.8%) women reported staring 
ANC in the first trimester of their pregnancy, 180 (66.6%) in the second trimester and 62 
(23.6%) in the third trimester (Figure 4.2). Two hundred and fifty three (94.4%) women 
initiated ART during pregnancy or labour and 15 (5.6%) started ART after delivery during 
breastfeeding.  
 
All women were followed-up until December 31st, 2015 with a median follow-up of 16.9 
(IQR 11.1-23.3) months. Babies born in the cohort were followed up until May 31st, 2016 
date of database closure for the exposed infants and those with complete 18 months 
follow up had their HIV antibody rapid test done to determine their final HIV status.  
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Patients’ status, site affiliation, baseline socio-demographic and HIV characteristics are 
provided in Table 4.1. In brief, 234 (87.3%) women were newly HIV diagnosed, the median 
age at ART initiation was 27 (IQR 24-31) years. The median CD4+ T-cell count at treatment 
initiation was 376 cells/mL (IQR 244 - 544.8) and 115 (43.0%) women had a CD4+ T-cell 
count less than 350 cells/mL.  ART was started in 234 (87.3%) ART naïve women and in 
four others (1.5%) who had been exposed to ARV during previous pregnancies. Thirty 
(11.2%) women who had already received Option A during their current pregnancy were 
also switched to Option B+( Figure 4.1). 
 
 
 
PhD thesis,  PASCAL NJI ATANGA  68 
 
 
Figure 4.1: Flow chart of study participants 
Figure shows how women attending ANC and IWC services from the five participating facilities 
were assessed for HIV status, counselled and tested for those with unknown status and how 
positive cases were eligible for Option B+ and enrolled into the study. 
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Figure 4.2: Distribution of women initiating Option B+ in Kumba health district by gestational age  
  at ANC enrollment. 
About three quarters of the women started ANC before 28 weeks of pregnancy, providing 
a good opportunity to initiate ARV before delivery. 
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Table 4.1: Socio-demographic and clinical characteristics of women who started lifelong 
ART for PMTCT Option B+ in Kumba Health District, South West Region, Cameroon 
between October 2013 and December 2014 . 
Variable Total 
Population 
N=268 
Women 
retained in care 
N=182 (67.9%) 
Women who 
discontinued 
treatment 
N= 65 (24.3%) 
Transferred to 
another ART 
clinic or died 
N=21 (7.8%) 
Age at ART initiation, median (IQR) 27 (24-31) 28 (24.75-32) 26 (23-30) 29 (21-31.5) 
15-24 years 76 (28.4) 47 (25.8) 22 (33.8) 7 (33.3) 
25 years and above  192 (71.6) 135 (74.2) 43 (66.2) 14 (67.7) 
Educational Level     
None 5 (1.9) 5 (2.7) 0 (0.0) 0 (0.0) 
Primary 147 (54.9) 93 (51.1) 41 (63.1) 13 (61.9) 
Secondary and above 116 (43.3) 84 (46.2) 24 (36.9) 8 (38.1) 
Marital Status     
Single 60 (22.4) 43 (23.6) 12 (18.5) 5 (23.8) 
Married 171 (63.8) 116 (63.7) 43 (66.2) 12 (57.1) 
Others (divorced, widow) 37 (13.8) 23 (12.6) 10 (15.4) 4 (19.1) 
Number of children     
None 65 (24.3) 45 (24.7) 15 (23.0) 5 (23.8) 
1 – 2 139 (51.9) 91 (50.0) 38 (58.5) 10 (47.6) 
3+ 64 (23.9) 46 (25.3) 12 (18.5) 6 (28.6) 
Cell phone possession     
Yes 24 (9.0) 16 (8.8) 6 (9.2) 2 (9.5) 
No 244 (91.0) 166 (91.2) 59 (90.8) 19 (90.5) 
Religious affiliation     
Traditional Christian churches (Catholic, 
Presbyterian and Baptist) 
163 (60.8) 109 (59.9) 38 (58.5) 16 (76.2) 
Pentecostals 100 (37.3) 69 (37.9) 26 (40.0) 5 (23.8) 
Muslim  5 (1.9) 4 (2.2) 1 (1.5) 0 (0.0) 
Occupation     
Unemployed 137 (51.1) 96 (52.7) 29 (44.6) 12 (57.1) 
Employed (formal public sector) 14 (5.2) 10 (5.5) 3 (4.6) 1 (4.8) 
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Employed (informal sector) or others 117 (43.7) 76 (41.8) 33 (50.8) 8 (38.1) 
HIV status     
Known HIV positive, not on ART  4 (1.5) 3 (1.6) 1 (1.5) 0 (0.0) 
Known HIV positive, already started on 
AZT (Option A) 
30 (11.2) 20 (11.0) 8 (12.3) 2 (9.5) 
New HIV diagnosis 234 (87.3) 159 (97.8) 56 (86.2) 19 (90.5) 
Missing 34 (12.7) 11 (6.2)  4 (19.0) 
Timing of ART initiation     
Breast feeding 15 (5.6) 8 (4.4) 7 (10.8) 0 (0.0) 
Antenatal Care (ANC or labour)  253 (94.4) 174 (95.6) 58 (89.2) 21 (100) 
ARV use at initiation     
Previously exposed to ART prophylaxis 33 (12.3) 20 (11.0) 11 (16.9) 2 (9.5) 
ART naïve  235 (87.7) 162 (89.0) 54 (83.1) 19 (90.5) 
CD4 cell count on initiation, median (IQR)  376 (244-544.8) 368 (210-578.5) 381 (277.8-604.5) 372(241-500) 
>350 cells/µL 153 (57.1) 104 (57.1) 37 (56.9) 12 (57.1) 
≤350 cells/µL 115 (42.9) 78 (42.9) 28 (43.1) 9 (42.9) 
WHO  stage     
WHO stage 1 226 (84.3) 157 (86.3) 52 (80.0) 17 (81.0) 
WHO stage 2 35 (13.1) 20 (11.0) 12 (18.5) 3 (14.3) 
WHO stage 3 7 (2.6) 5 (2.7) 1 (1.5) 1 (4.8) 
Health Facility Type     
Small sites with high  staff  turnover 49 (18.3) 24 (13.2) 19 (29.2) 6 (28.6) 
Larger sites with moderate staff turnover 219 (86.8) 158 (86.8) 46 (70.8) 15 (71.4) 
 Data are in numbers and percentages [n (%)], unless stated otherwise 
Socio-demographic and clinical characteristics of women who were retained in care, 
discontinued treatment, died or transferred out to other clinics. 
4.2 Retention in care and factors related with treatment discontinuation  
Of the 268 women included in the study, 86 (32.0%) did not complete study procedures. 
Overall, 19 (7.1%) were self-transferred to other ART clinics for whom no further 
treatment information was available, 2 (0.7%) died and 65 (24.3%) women discontinued 
antiretroviral Option B+ therapy. Socio-demographic and HIV characteristics of women 
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who were retained in care, discontinued treatment, self-referred or died are shown in 
Table 4.1. At months 6, 32 (13.0%) women had discontinued treatment, of those 14 
(43.8%) did not return for any refill appointment, and 24 (75.0%) had discontinued 
treatment within 3 months of ART initiation. Twenty (8.1%) women discontinued 
treatment between months 6 and 12, and cumulatively 52 (21.1%) women had 
discontinued treatment by month 12 of ART initiation. Numbers and percentages of 
women with treatment discontinuation by time and site are shown in Table 4.2. 
Treatment discontinuation at 12 months varied across the five sites ranging from 12.0% to 
36.4% and the two smaller sites with a high staff turnover recorded the highest 
discontinuation rates (Table 4.2). Age presented as a significant predictor of treatment 
discontinuation in the clustering adjusted linear model [OR (95% CI) = 1.5 (1.1, 2.0), p = 
0.020] with younger women more likely to discontinue their treatment but this 
significance was lost in the multivariate analysis.  
 
Comparing treatment discontinuation before and after delivery it came out clear as can be 
seen on the Kaplan Meier curves (Figure 4.3) that women were three times more likely to 
discontinue their treatment after delivery than before delivery and this difference was 
statistically significant in a Cox proportional hazard model [HR (95% CI); 3.0 (1.7, 5.2), p = 
0.012)]. 
 
Overall retention-in-care was estimated at 6 and 12 months after ART initiation using a 
time-to-event analysis to efficiently use all available data from each woman in the cohort. 
Including all 268 women in the Kaplan Meier analysis, 88.0% of women were still in care at 
6 months and 81.1% were still in care at 12 months after ART initiation (Figure 4.4). 
Retention-in-care was significantly lower in women attending a small facility with a high 
staff turnover (83.0% and 68.3% at months 6 and 12, respectively) when compared to 
those attending a larger facility with a moderate staff turnover (89.2% and 84.1% at 
months 6 and 12, respectively) see Figure 4.7. Follow-up information on retention-in-care 
beyond 12 months was available for 201 women until 18 months and 185 women until 24 
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months with observed retention rates of 74.2% and 73.3%, respectively.  In the Cox 
proportional hazard model adjusting  for baseline age, CD4 count at initiation, educational 
level, marital status and timing of ART initiation low scale facility type with high staff turn-
over were identified as a significant predictor for discontinuation of Option B+ procedures 
[HR (95% CI) = 2.0 (1.2,3.4), p = 0.012].This was confirmed in the clusters adjusted 
generalized estimating equation within the generalized linear model that adjusted for age, 
education level, marital status, timing of ART initiation, CD4 count at initiation [aOR (95% 
CI) = 2.5 (1.6, 3.9), p < 0.001]. 
 
Retention-in-care was lower in women initiating ART at breastfeeding than those initiating 
ART during ANC but this difference was not statistically significant [HR (95% CI) = 2.1 
(0.9,4.6), p = 0.063]. This can be seen on the Kaplan Meier curves for women initiating ART 
at breastfeeding which remained below that for women initiating ART at ANC (Figure 4.6).  
4.3 Reasons for treatment discontinuation 
Of the 65 women who discontinued treatment, 29 (44.6%) were LTFU and the 36 (55.8%) 
who had intentionally stopped treatment and were successfully reachable were asked for 
reasons why treatments were stopped. The main reasons advanced included: (i) denial of 
HIV status, stigma and discrimination 19 (52.8%), (ii) religious reasons 9 (25.0%), and (iii) 
lack of transport fare to come to the clinic 4 (11.1%). Four (11.1%) women declined to 
provide any reason. All women reached were counselled by PE on the importance of 
resuming treatment. All those who had stopped treatment for religious reasons did not 
see any reason for returning and simply declared that their faith was going to heal them. 
Ten (52.6%) women who had stopped because of status denial, stigma and discrimination 
accepted to return for their treatment. 
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Figure 4.3: Probability of women discontinuing treatment before and after delivery. 
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Table 4.2: Treatment discontinuation (lost to follow-up & active treatment interruption) 
by sites and months after ART initiation following Option B+ procedures 
Health Facility Transferred 
to another 
ART clinic or 
died 
Women 
analysed 
Months to treatment discontinuation 
By month 
6 
 
Between 
6 and 12 
months 
Cumulative 
by month 
12 
Between 
12 and 27 
months 
Larger facilities 
with moderate 
staff turnover 
CMA K 6 75 4 (5.3) 5 (6.7) 9 (12.0) 3 (4.0) 
PHC K 6 66 6 (9.1) 6 (9.1) 12 (18.2) 4 (6.1) 
DHK 3 63 14 (22.2) 2 (3.2) 16 (25.4) 2 (3.2) 
Smaller facilities 
with high staff  
turnover 
CMA N 3 21 4 (19.0) 3 (14.3) 7 (33.3) 1 (4.8) 
CHC F 3 22 4 (18.2) 4 (18.2) 8 (36.4) 3 (13.6) 
Total 21 247 32 (13.0) 20 (8.1) 52 (21.1) 13 (5.3) 
Data are in numbers and percentages [n (%)] 
 CMA K: Urban integrated Health Center Kumba, PHC K: Presbyterian Hospital Kumba, DHK: District Hospital 
Kumba, CMA N: Integrated Health Center Ntam, CHC F: Catholic Health Center Fiango.  
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Table 4.3: Risk factors associated with treatment discontinuation in women who were lost to follow- up or intentionally 
stopped their treatment after ART initiation following Option B+ procedures. 
 
Characteristics Retained Discontinued Univariate analysis Multivariate analysis 
OR (95% CI) P-value aOR (95% CI) P-value 
Age (years)       
15-24 years 47 (25.7) 22 (33.8) 1.5 (1.1-2.0) 0.020 1.6 (0.9-2.8) 0.091 
25 years and above 135 (74.2) 43 (66.2) 1  1  
Educational Level       
None 5 (2.7) 0 (0.0) -  -  
Primary 93 (51.1) 41 (63.1) 1.5 (0.8-3.1) 0.223 1.6 (0.9-2.8) 0.153 
Secondary and above 84 (46.2) 24 (36.9) 1  1  
Marital status       
Single 43 (23.6) 12 (18.5) 1  1  
Married/cohabiting 116 (63.7) 43 (66.2) 1.6 (0.9-2.8) 0.131 1.7 (1.0—2.8) 0.068 
Others (divorce or widow) 23 (12.6) 10 (15.4) 1.2 (0.7-1.9) 0.506 1.1 (0.6-2.0) 0.897 
Timing of ART initiation       
Antenatal Care (ANC or labour) 174 (95.6) 58 (89.8) 1  1  
Breast feeding 8 (4.4) 7 (10.8) 2.6 (0.6-11.5) 0.201 2.8 (0.6-12.8) 0.197 
CD4 at initiation       
>350 cells/µL 78 (42.9) 28 (43.1) 1  1  
≤350 cells/µL 104 (57.1) 37 (56.9) 1.0 (0.6-1.6) 0.971 1.1 (0.7-1.7) 0.741 
Health Facility Type       
Larger sites with moderate staff 
turnover 
158 (86.8)  46 (70.8)  1  1  
Small sites with high  staff  
turnover 
24 (13.2) 19 (29.2) 2.7 (1.7-4.4)  <0.001 2.5 (1.6-3.9)  < 0.001 
Data are in numbers and percentages [n (%)] 
The statistics in the table were generated using the generalised estimating equation within the generalised linear model 
accounting for correlation within clusters within health facilities. The point estimates in the multivariate analysis were adjusted 
for baseline age, educational level, marital status, timing of ART initiation and CD4 count at initiation.
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Figure 4.4: Time to treatment discontinuation of the overall study participants 
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Figure 4.5: Time to treatment discontinuation in women 15-24 years and those 25 years  
  and above.  
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Figure 4.6: Time to treatment discontinuation in women initiating ART at antenatal care 
(ANC) and those initiating ART during the breastfeeding period. 
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Figure 4.7: Time to treatment discontinuation in women attending small facilities with a  
  high staff turnover and those attending larger facilities with moderate staff  
  turnover. 
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4.4 Service providers' turnover in Option B+ service provision 
At the three large facilities only half of the trained staff were still providing PMTCT Option 
B+ services 6 months after training, and at the two small sites this was only a single staff 
member out of the four trained. It was only at one of the larger facilities that the staff 
trained and still providing services were exclusively managing women on Option B+. At all 
the four other sites the few staffs that remained were additionally tasked with multiple 
other functions, including on call duties resulting in absence or very few staff to provide 
PMTCT services at the following day.  At some of these sites the peer educators who were 
assigned to follow-up on missed clinic appointments were found dispensing ARVs to 
women. 
4.5 Adherence to ART 
Adherence to lifelong ART was assessed for study participants who were available and 
responded to the adherence questionnaire and interpreted the visual analogue scale at 6 
month and 12 months using a composite adherence score (CAS). The adherence at 6 
months was the result of the CAS at 6 months and that at 12 months was the results of 
the CAS at 12 months.  Women LTFU, died, transferred out to other ART facilities or had 
stopped treatment were excluded from the analysis. At 6 months 217 participants were 
assessed for adherence. Overall 128 (59.0%)  women had a high adherence, 69 (31.8%) 
had a moderate adherence and 20 (9.2%) reported low adherence. Comparing all the 
adherence measures pharmacy refills tended to over estimate adherence followed by self 
report and the the visual analogue scale. At 12 months only 185 women were assessed for 
adherence. In all 116 (62.7%) had a high adherence, 48 (25.9%) had a moderate 
adherence and 21 (11.4%) had low adherence indicating a slight increase towards high 
adherence at month 12. Twelve months adherence was further dichotomized into good 
and poor adherence after validation with virologic outcome at 12 months. In all 164 
(88.6%) women were assessed with good adherence and 21 (11.4%) had poor adherence. 
Younger women [OR (95%CI); 2.8 (0.9, 8.7)] and women attending Pentecostal churches 
[OR (95% CI); 6.1 (2.1, 17.6)] were more likely not to adhere to their ART treatment when 
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compared to older women and women who attended traditional christian churches. Also 
women who had just a primary level of education [OR (95%CI); 3.6 (2.2, 6.1)] and women 
employed in the informal sector [OR(95%CI); 2.1 (1.6-2.8)] were more likely to be non-
adherent on treatment when compared with women with a secondary or higher level of 
education and those not employed (Table 4.5). After adjusting for demographics and 
other confounders, younger age, attending a Pentecostal church, low level of education 
and employment in the informal sector remained significantly associated with poor 
treatment adherence (table 4.6). 
 
Assessing adherence both at two and three levels, adherence was not significantly 
associated with CD4+ T-cell count at treatment initiation (Tables 4.4 and 4.5). We thus 
failed to reject our null hypothesis. 
 
Table 4.4: Adherence with different measures in three levels categorised by CD4- T cell 
count at treatment initiation 
Adherence N CD4 count 
> 350 cells/µL 
N (%) 
CD4 count 
≤ 350cell/µL 
N (%) 
Six Months 217 127 (58.5) 90 (41.5) 
Pharmacy refill    
Low 17 (7.8) 9 (7.1) 8 (8.9) 
Moderate 17 (7.8) 8 (6.3) 9 (10.0) 
High 183 (84.3) 110 (86.6) 73 (81.1) 
Self-report    
Low 15 (6.9) 7 (5.5) 8 (8.9) 
Moderate 43 (19.8) 30 (23.6) 13 (14.4) 
High 159 (73.3) 90 (70.9) 69 (76.7) 
VAS    
Low 12 (5.5) 6 (4.7) 6 (6.7) 
Moderate 55 (25.3) 32 (25.2) 23 (25.6) 
PhD thesis, PASCAL NJI ATANGA   83 
 
High 150 (69.1) 89 (70.1) 61 (67.8) 
CAS    
Low 20 (9.2) 10 (7.9) 10 (11.1) 
Moderate 69 (31.8) 41 (32.3) 28 (31.1) 
High 128 (59.0) 76 (59.8) 52 (57.8) 
Twelve Month 185 109 76 
Pharmacy refill    
Low 23 (12.4) 14 (12.8) 9 (11.8) 
Moderate 12 (6.5) 7 (6.4) 5 (6.6) 
High 150 (81.1) 88 (80.8) 62 (81.6) 
Self-report    
Low 11 (5.9) 7 (6.4) 4 (5.3) 
Moderate 31 (16.8) 19 (17.4) 12 (15.8) 
High 143 (77.3) 83 (76.2) 60 (78.9) 
VAS    
Low 14 (7.6) 5 (4.5) 9 (11.8) 
Moderate 36 (19.5) 26 (23.9) 10 (13.2) 
High 135 (73.0) 78 (71.6) 57 (75.0) 
CAS    
Low 21 (11.4) 11 (10.1) 10 (13.2) 
Moderate 48 (25.9) 31 (28.4) 17 (22.4) 
High 116 (62.7) 67 (61.5) 49 (64.5) 
 
Data are in numbers and percentages [n (%)] 
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Table 4.5: Risk factors of  poor adherence to treatment at 12 months after initiating 
Option B+ in Kumba health district. 
Characteristics N  Poor 
adherence 
Good 
adherence  
OR (95%CI) P-value 
Number of patients 185 21 (11.4) 164 (88.6)   
Age at ART initiation       
15-24 years 50 (27.0) 10 (47.6) 40 (24.4) 2.8 (0.9-8.7) 0.072 
25 years and above  135 (73.0) 11 (52.4) 124 (75.6) 1  
Educational Level      
None 4 (2.2) 0 (0.0) 4 (2.4) -  
Primary 91 (49.2) 16 (76.2) 75 (45.7) 3.6 (2.2-6.1) <0.001 
Secondary and above 90 (48.6) 5 (23.8) 85 (51.8) 1  
Marital Status      
Single 43 (23.2) 5 (23.8) 38 (23.2) 1  
Married/cohabiting 140 (75.7) 16 (76.2) 124 (75.6) 1.0 (0.4-2.9) 0.971 
Others (divorced, widow) 2 (1.1) 0 (0.0) 2 (1.2) -  
Occupation      
Unemployed 78 (42.2) 5 (23.8) 73 (44.5) 1  
Employed formal sector 9 (4.9) 0 (0.0) 9 (5.5) -  
Employed informal 
sector 
98 (53.0) 16 (76.2) 82 (50.0) 2.1 (1.6-2.8) <0.001 
Number of children      
None 46 (24.9) 4 (19.0) 42 (25.6) 1.2 (0.3-4.8) 0.759 
1 – 2 97 (52.4) 14 (66.7) 83 (50.6) 2.2 (0.6-8.2) 0.242 
3+ 42 (22.7) 3 (14.3) 39 (23.8) 1  
Cell phone possession      
No 14 (7.6) 1 (4.8) 13 (7.9) 0.6 (0.1-4.6) 0.606 
Yes 171 (92.4) 20 (95.2) 151 (92.1) 1  
Religious affiliation      
Traditional Christian 
churches (Catholic, 
Presbyterian and Baptist) 
108 (58.4) 5 (23.8) 103 (62.8) 1  
Pentecostals 70 (37.8) 16 (76.2) 54 (32.9) 6.1 (2.1-17.6) < 0.001 
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Muslim  5 (2.7) 0 (0.0) 5 (3.0)   
Timing of ART initiation      
Breast feeding 7 (3.8) 0 (0.0) 7 (4.3) - - 
Antenatal Care (ANC or 
labour)  
178 (96.2) 21 (100) 157 (95.7)   
CD4 cell count on 
initiation, 
     
≤350 cells/µL 76 (41.1) 10 (47.6) 66 (40.2) 1.4 (0.5-3.8) 0.575 
>350 cells/µL 109 (58.9) 11 (52.4) 98 (59.8) 1  
WHO  stage      
WHO stage 1 160 (86.5) 18 (85.7) 142 (86.6) 1  
WHO stage 2 21 (11.4) 3 (14.3) 18 (11.0) 0.8 (0.2-2.8) 0.683 
WHO stage 3 & 4 4 (2.2) 0 (0.0) 4 (2.4) -  
Health Facility Type      
Small sites with high  
staff  turnover 
26 (14.1) 4 (19.0) 22 (13.4) 1.5 (0.3-7.1)  0.597 
Larger sites with 
moderate staff turnover 
159 (85.9) 17 (81.0) 142 (86.6) 1  
 
Data are in numbers and percentages [n (%)] 
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Table 4.6: Risk factors of poor adherence to treatment at 12 months following Option B+ initiation with adjusted OR in Kumba 
health district. 
Characteristics Poor 
adherence 
Good 
adherence  
Univariate analysis Multivariate analysis 
OR (95% CI) P-value aOR (95% CI) P-value 
Age (years)       
15-24 years 10 (47.6) 40 (24.4) 2.8 (0.9-8.7) 0.072 4.3 (1.2-15.3) 0.022 
25 years and above 11 (52.4) 124 (75.6) 1  1  
Educational Level       
None 0 (0.0) 4 (2.4) -  -  
Primary 16 (76.2) 75 (45.7) 3.6 (2.2-6.1) < 0.001 2.7 (1.9-3.9) < 0.001 
Secondary and above 5 (23.8) 85 (51.8) 1  1  
Occupation       
Unemployed 5 (23.8) 73 (44.5) 1  1  
Employed formal sector 0 (0.0) 9 (5.5) -  -  
Employed informal sector 16 (76.2) 82 (50.0) 2.1 (1.6-2.8) < 0.001 3.5 (2.7-4.7)  < 0.001 
Religious affiliation       
Traditional Christian churches 
(Catholic/Presbyterian and Baptist) 
5 (23.8) 103 (62.8) 1  1  
Pentecostals 16 (76.2) 54 (32.9) 6.1 (2.1-17.6)  < 0.001 5.8 (3.5-16.2) <0.001 
Muslim  0 (0.0) 5 (3.0) -  -  
CD4 at initiation       
>350 cells/µL 10 (47.6) 66 (40.2) 1.4 (0.5-3.8) 0.575 2.3 (0.9-5.7) 0.078 
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Data are in numbers and percentages [n (%)], OR (odd ratio), aOR (adjusted odd ratio)]. 
 
The statistics in the table were generated using the generalised estimating equation within the generalised linear model 
accounting for correlation within clusters within heath facilities. The point estimates in the multivariate analysis were adjusted 
for baseline age, educational level, occupation, religious affiliation, timing of ART initiation, CD4 count at initiation and facility 
type.
≤350 cells/µL 11 (52.4) 98 (59.8) 1  1  
Health Facility Type       
Larger sites with moderate staff 
turnover 
4 (19.0) 22 (13.4) 1.5 (0.3-7.1)  0.597 1.4 (0.4-4.9) 0.583 
Small sites with high  staff  turnover 17 (81.0) 142 (86.6) 1  1  
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4.6 Correlation between different adherence measures 
The different adherence maesures were all correlated with each other and all were 
significantly correlated to the composite adherence score with a Spearman correlation 
ranging from 0.36 to 0.83 (p < 0.001 for all comparisms). However, the highest linear 
correlation was observed between the CAS and VAS which remained consistent both at 6 
and 12 months with a Spearman correlation of  r = 0.83 (Tables 4.7 and 4.8). 
 
Table 4.7: Correlation coefficient between different adherence measures at 6 months 
 Phamacy refill Self-report VAS CAS 
Pharmacy refill 1.00 0.42 0.52 0.62 
Self-report 0.42 1.00 0.52 0.76 
VAS 0.52 0.52 1.00 0.83 
CAS 0.62 0.76 0.83 1.00 
 
Table 4.8: Correlation coeffivient between the different adherence measures at 12 
months 
 Pharmacy refill Self-report VAS CAS 
Pharmacy refill 1.00 0.36 0.65 0.72 
Self-report 0.36 1.00 0.49 0.71 
VAS 0.65 0.49 1.00 0.83 
CAS 0.72 0.71 0.83 1.00 
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4.7 Potential causes of missing treatment and reminders of drug taking 
Among the women who were available at 12 months and responded to the adherence 
evaluation questionnaire they were also asked what could potentially cause them to miss 
taking medications and what were some of those things that also reminded them to take 
their medication. This is one of the useful aspects of the self-report assessment which is 
not feasible with the other assessment measures. Concerning the first question what 
could potentially cause them to miss taking medicines 121 (65.4%) women provided 
explanations. Some women gave more than one reason for missing to take their 
medications. Frequently cited reasons were forgetfulness 43 (35.5%), travel away from 
home 29 (24.0%) and lack of transport to the clinic 28 (23.1%). Stigmatisation, being 
distracted by the baby, being away for work and being involved in church or other social 
activites were also advanced ( Table 4.9 ). 
 
Table 4.9: Reasons for potentially missing to take ART amongst women on Option B+ in 
Kumba health district. 
Reasons for potentially not taking medications N % Respondents 
Total women 185  
Non respondents 64 34.6 
Respondents 121 65.4 
− Away for work 5 4.1 
− Forgetfulness 43 35.5 
− Lack of transport to come to pick up ARV 28 23.1 
− Travel away from home 29 24.0 
− Baby distraction 5 4.1 
− Side effects mainly dizziness 6 5.0 
− Stigmatisation 5 3.3 
− Involved in church or social activities 4 4.1 
− Lack of food 2 1.7 
− Child Vaccination is over 1 0.8 
 
NB* Percentatges are out of those who responded to each question. Some women gave more than one 
reason so total may add up to over 100. 
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On the other hand women were more ready to share some of the things that reminded  
them to better take their medications. To the question what helps remind you to take 
your medications 172 (94.0%) women provided responses. The most frequently cited was 
the use of cell phone alarms 64 (37.2%), secondly most women said drug taking has 
become a routine in their lifes so it occurs more like an instinct 63 (36.6%) and the use of 
alarm clocks 22 (18.8%). Among the less frequently cited, interestingly 13 (7.6%) women 
declared that they were being reminded by their husbands, 4 (3.3%) relied on a TV series 
why another 4 (3.3%) had their drugs by their bedside (Table 4.10). 
 
Table 4.10: Means of reminding women to take ART amongst women on Option B+ in 
Kumba Health district. 
Treatment reminder N % Respondents 
Total women 185  
Non respondents 13 7.0 
Respondents 172 93.0 
− Phone alarm 64 37.2 
− Clock alarm  22 18.8 
− Become a daily routine 63 36.6 
− Husband 13 7.6 
− TV series 4 2.3 
− Drugs by my bedside 4 2.3 
− Sister/Mother 1 0.6 
− Church bell/Prayer time 1 0.6 
 
NB* Percentatges are out of those who responded to each question and many women gave multiple 
responses so may add up to over 100 
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4.8 Viral Load 
All clients who were retained-in-care at 12 months were eligible for viral laod collection. 
Overall, 165 (90.7%) women had their viral loads samples collected at 12 months. Those 
whose viral loads samples were not collected were either missed out because they did not 
attend clinic on the day the team collecting the viral load samples was around or they had 
collected their medications earlier on because they were either traveling or came from far 
off distances. Of the 165 women who had their VL done, 139 (84.2%) were undetectable 
i.e. <40 copies/µL, 14 (8.5%) had VL between 40-999 copies/µL and 12 (7.3%) had VL 
above 1,000 copies/µL. We used the WHO definition (Viral suppression < 1,000 copies/µL) 
to classify clients as either virologically suppressed or not and 153 (92.7%) women were 
virologically suppressed. Women with VL between 40-999 copies/µL were considered to 
be having a blip and were counselled accordingly. For those who had VL above 1,000 
copies/µL they were counselled and adequately supported for adherence and a second 
sample was recollected after 4 weeks. Samples were successfully recollected for 8 out of 
the 12 women who were virologically unsupressed. Treatment failure was confirmed in 
five women whose second VL came back unsuppressed and they were immediately 
referred to the mian HIV treatment centre of the health district for consideration of 
switching them to second line therapy. Three women were resuppressed after counselling 
and adherence reinforcement. There was no clear association between women’s socio-
demographic or HIV characteristics and virologic suppression (Table 4.11).  
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Table 4.11: Virologic outcome for pregnant and breastfeeding women retained in care at 
12 months after initiating Option B+ in Kumba health district. 
Characteristics N  Unsuppressed 
VL ≥ 1,000copies/µL 
N (%) 
Suppressed 
VL < 1,000 copies/µL 
N (%) 
P-value 
Number of patients 165 12 (7.3) 153 (92.7%)  
Age at ART initiation      
15-24 years 44 (26.7) 5 (41.7) 39 (25.5) 0.306 
25 years and above  121 (73.3) 7 (58.3) 114 (74.5) Ref. 
Educational Level     
None 4 (2.4) 0 (0.0) 4 (2.6) - 
Primary 80 (48.5) 6 (50.0) 74 (48.4) 0.851 
Secondary and above 81 (49.1) 6 (50.0) 75 (49.0) Ref. 
Marital Status     
Single 38 (23.0) 2 (16.7) 36 (23.5) Ref. 
Married/cohabiting 125 (75.8) 10 (83.3) 115 (75.2) 0.782 
Others (divorced, widow) 2 (1.2) 0 (0.0) 2 (1.3) - 
Number of children     
None 40 (24.2) 3 (25.0) 37 (24.2) Ref. 
1 – 2 85 (51.6) 9 (75.0) 76 (49.7) 0.104 
3+ 40 (24.2) 0 (0.0) 40 (26.1) - 
Cell phone possession     
No 14 (8.5) 1 (8.3) 13 (8.5) 1.00 
Yes 151 (91.5) 11 (91.7) 140 (91.5) Ref. 
Religious affiliation     
Traditional Christian churches 
(Catholic, Presbyterian and 
Baptist) 
99 (60.0) 5 (41.7) 94 (61.4) Ref. 
Pentecostals 62 (37.6) 7 (58.3) 55 (35.9) 0.277 
Muslim  4 (2.4) 0 (0.0) 4 (2.6) - 
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Timing of ART initiation     
Breast feeding 6 (3.6) 0 (0.0) 6 (3.9) - 
Antenatal Care (ANC or labour)  159 (96.4) 12 (100) 147 (96.1) Ref. 
CD4 cell count on initiation,      
>350 cells/µL 70 (42.4) 5 (41.7) 65 (42.5) Ref. 
≤350 cells/µL 95 (57.6) 7 (58.3) 88 (57.5) 0.956 
WHO  stage     
WHO stage 1 142 (86.1) 11 (91.7) 131 (85.6) Ref. 
WHO stage 2 19 (11.5) 0 (0.0) 19 (12.4) - 
WHO stage 3 & 4 4 (2.4) 1 (8.3) 3 (2.0) 0.183 
Health Facility Type     
Small sites with high  staff  
turnover 
21 (12.7) 3 (25.0) 18 (11.8) 0.185 
Larger sites with moderate staff 
turnover 
144 (87.3) 9 (75.0) 135 (88.2) Ref. 
 
Data are in numbers and percentages [n (%)] 
4.9 Adherence and virologic outcome 
Considering the fact that women who were classified as highly adherent and those who 
were considered moderately adherent both had similarly high virological suppression, 
adherence at 12 months was regrouped into two categories such that high and moderate 
were classified as good adherence while low was classified as poor adherence. There was 
a strong association between virologic suppression and  adherence using all measures of 
adherence at 12 months.  Women with poor adherence were 16 times more likely not to 
have viral suppression at 12 months compared with those who were  adherent when 
adherence was assessed with CAS [OR (95% CI) = 16.0 (4.3, 59.7), p < 0.001]. Poor 
adherence is thus a strong predictor of virologic failure (Table 4.12).  
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Table 4.12: Association between adherence and virologic suppression in pregnant and 
breastfeeding women at 12 months after ART initiation. 
Adherence N(165) Unsuppressed 
VL (≥ 1000 
copies/µL)  
12 (7.3) 
Suppressed VL 
(< 1000 
copies/µL)  
153 (92.7) 
OR (95%CI) P-value 
Pharmacy refill      
Poor adherence 17 (10.3) 6 (50.0) 11 (7.2) 12.9 (3.5-46.7) < 0.001 
Good adherence 148 (89.7) 6 (50.0) 142 (92.8) 1  
Self-report      
Poor adherence 7 (4.2) 4 (33.3) 3 (2.0) 25.0 (4.7-131.1) < 0.001 
Good adherence 158 (95.8) 8 (66.7) 150 (98.0) 1  
VAS      
Poor adherence 10 (6.1) 6 (50.0) 4 (2.6) 37.3 (8.3-167.5) < 0.001 
Good adherence 155 (93.9) 6 (50.0) 149 (97.4) 1  
CAS      
Poor adherence 15 (9.1) 6 (50.0) 9 (5.9) 16.0 (4.3-59.7) < 0.001 
Good adherence 150 (90.9) 6 (50.0) 144 (94.1) 1  
 
Data are in numbers and percentages [n (%)] 
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4.10 Early infant diagnosis  
A total of 253 (94.4%) life births occurred in the cohort. Two hundred and twenty infants 
had their PCR done giving an HIV-DNA PCR uptake of 86.9%.  Of these, 184 (83.6%) were 
collected between 5 and 8 weeks of life and the rest 36 (16.4%) were collected after 8 
weeks (Figure 4.8). The mean age at DNA-PCR collection was 8 (range: 5-59) weeks. The 
mean turn arround time for result was 6 (range: 2-34) weeks. Most PCR results (80.9%) 
were delivered to the collecting facility within 8 weeks of sample collection (Figure 4.9). 
Four (1.8%) children tested PCR-positive; two males and two females. Three of these 
children were exclusively breastfed and one was mixed fed. All four cases were delivered 
by the vaginal route. There was no difference between infection from babies of mothers 
initaiting ARV with a higher CD4+ T-cell count when compared to those with low a CD4+ T-
cell count. There was also no association between socio-demographic and clinical 
characteristics and HIV infection in children.  
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Figure 4.8:  Timing of DBS collection in HEI delivered in the cohort of HIV-positive women 
 initiating Option B+ in Kumba health district 
Most infants (83.7%) had their DBS samples collected before the second month of life with 
80.9% collection done according to national guideline (6-8 week). 
PhD thesis, PASCAL NJI ATANGA   97 
 
 
 
 
 
Figure 4.9:  Time from DBS collection to delivery of PCR results to health facility (PCR 
 Turnaround time) in HEI in the cohort. 
 
More than four fith (80.9%) of PCR results were processed and returned to the collecting 
facilities on or before two months of sample collection. 
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4.11 Pregnacy outcomes 
Of the 268 women who were enrolled in the study, 15 (5.6%) were already in the 
postpartum period and breastfeeding while 231 (91.3%) life births occurred. The following 
pregnancy outcomes were recorded; 7 (2.8%)  women had an abortion, 8 (3.2%) had 
stillbirths and two (0.7%) women died. Among the life births, the prevalence of low birth 
weight was 7.1% and that of premature births was 6.7%. There was no association 
between birth weight, gestational age at delivery and HIV infection in children. 
4.12 Final HIV transmission 
At database closure for HIV exposed infants born in this cohort, 122 (51.9%) children had a 
follow up of 18 months or more so had a HIV antibody rapid test done to confirm their 
final HIV status. Only one child of the 122 collected samples had a positive rapid test 
giving a 18 month HIV transmission rate of 0.8%. The cummulative overall MTCT rate in 
our study was 2.6%. However, this could not be conclusive since just about 50% of the 
children were followed up to 18 months  and received a final rapid test. The lone child 
who was infected after an HIV antibody rapid test at 18 months, the mother’s adherence 
at six and twelve months were perfect and she had an undetectable viral load at 12 
months. 
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5. Discussion 
5.1 HIV counselling and testing (HCT) and antiretroviral therapy (ART) uptake  
With Option B+ being piloted in Cameroon, facility-level uptake of HTC, ART, retention-in-
care and adherence to treatment needed to be determined and treatment 
discontinuation classified and evaluated. Facility-level HIV testing and counselling uptake 
(98.5%) was high, but ART uptake at 96.8% was even much higher than the 81.9% 
reported prior to the introduction of Option B+ from programmatic data (CNLS, 2014). 
With the introduction of Option B+ most countries have reported improvements in 
facility-level uptake of HTC and ART (Kieffer et al., 2014; Kim, Ahmed, Hosseinipour, et al., 
2015).  This high HTC and ART uptake needs to be consolidated into real programme 
benefit and success by having in place systems that will continually support women with 
the necessary psychosocial and physical support to maintain them in care and improve 
adherence. Starting treatment is very important but poor retention-in-care undermines 
programme and patient outcome including achieving sustained viral suppression which is 
one of the main and ultimate goals of the UNAIDS 90-90-90 agenda to be achieved by 
2020 (UNAIDS, 2014a). 
5.2 Retention-in-care 
Retention-in-care was found to drop progressively within the first year after ART initiation 
with 88.0% and 81.1% of women still in care at 6 and 12 months, respectively. The 6 and 
12 months retention rates obtained in this study were slightly higher than that previously 
reported in Malawi 82.6% and 76.9%  respectively (CDC, 2013). This observed difference in 
the retention might not be significant but could be explained by the study methodology, 
as this study was conducted in parallel to a newly launched pilot activity in Cameroon 
which provided recently implemented resources and trained staff, while in Malawi the 
retention rates were calculated from programmatic data routinely collected by the sites. 
However, early implementation in Uganda also reported a 88.0% retention rate at 6 
months (Kieffer et al., 2014).  
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In general retention in ART care tends to drop overtime (Cornell et al., 2010; Rosen, Fox, & 
Gill, 2007) and is especially challenging in women who are pregnant or breastfeeding 
(Clouse et al., 2014). However, in this study we observed a better retention rate at 12 
months as compared to studies that suggest that women who initiate ART while pregnant 
have poorer retention in HIV care than men and non-pregnant women (Kaplan, Orrell, 
Zwane, Bekker, & Wood, 2008; Wang et al., 2011).  These results, just like those from 
others settings, might point out the beneficial impact of focused adherence support and 
defaulter tracing for improved overall ART retention in pregnant or breastfeeding women.  
In this pilot project peer educators were hired and trained to follow-up pregnant women 
and mother-infant pairs during pregnancy and post-partum to reduce LTFU. Two to three 
weeks after missing an appointment the peer educators immediately embarked on tracing 
the woman either by phone calls or through home visits if she gave her consent to be 
traced. Such tracing programmes have proofed beneficial in bringing women back to care 
in many other sub-Saharan African settings (Ebuy et al., 2014; Tweya et al., 2014). 
Most of the women who did not complete the study procedures dropped out after 
delivery just like reported in other studies (Jean B Nachega et al., 2012). Treatment 
discontinuation was highest within the first 6 months after treatment initiation and 14 
(43.8%) of women who discontinued their treatment during this period never returned to 
any refill visit. This was similar to reports from other African countries where most of the 
treatment discontinuations were early dropouts (Schnack et al., 2016; Tweya et al., 2014). 
Some of these early dropouts might never had started treatment at all, hence supporting 
concerns of same day treatment initiation following HIV diagnosis as recommended within 
the Option B+ guidelines, implying that these women were not adequately prepared to 
start lifelong ART.   
 
Treatment preparedness and readiness to start and commit to adhere to lifelong ART is 
critical for treatment success (Gebrekristos, Mlisana, & Karim, 2005), and loss to 
treatment retention was reported to be higher in women starting on Option B+ in Malawi 
as compared to those who were already on ART before pregnancy (Haas, Tenthani, et al., 
PhD thesis, PASCAL NJI ATANGA   101 
 
2016; Kim, Ahmed, & Abrams, 2015).  In Malawi a 17% LTFU at 6 months after ART 
initiation was observed with a better retention-in-care in women who did not start ART on 
the same day of HIV diagnosis or who received focused counselling (Tenthani et al., 2014). 
This further emphasizes the need to have the client adequately prepared that she 
understands the implications of lifelong ART. The decision to initiate ART might be too 
overwhelming and complex to take immediately after HIV diagnosis. In a commentary on 
women concerns about initiating Option B+, Matheson and colleagues argued,  “if women 
are not adequately prepared they can experience various human right violations including 
lack of informed consent, involuntary or coercive HIV testing, limited treatment options, 
termination of pregnancy or coerced sterilization and pressure to start treatment” 
(Matheson et al., 2015). World Health Organisation suggests that it is good practice to 
make a lot of efforts to reduce the time between HIV diagnosis and ART initiation based 
on the assessment of the person’s readiness to start treatment. If the person decides not 
to start ART immediately, counselling should continue and the advantages of early 
initiation adequately exposed to the client and ART can be proposed at subsequent clinics 
(WHO, 2016). 
 
With the very busy nature of our ANC and IWCs, and given the limited number of staff 
available for Option B+, service delivery, post-test counselling and adherence preparation 
could have been inadequate.  This assumption was supported by our data indicating that 
high staff turnover and smaller facilities significantly affected retention-in-care and 
treatment leading to a greater likelihood of ART discontinuation. Health system factors 
like overburdened staff, long clinic waiting time and ability to capture and report data 
have been shown to affect retention-in-care at larger health facilities and ART 
programmes (Cornell et al., 2010). Fewer staff and multiple tasking was the main reason 
for lower retention at the smaller facilities. These facilities had only one Option B+ staff to 
provide services 6 months into the project. This same staff also had to perform all other 
duties. In one of the high volume site with the lowest discontinuation rate, Option B+ staff 
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was completely relieved from all other duties, such as on call duties thus avoiding absence 
or fewer staff to provide PMTCT services on the following day.   
 
Socio-demographic and HIV related factors in this study were not significantly associated 
with treatment discontinuations.  Other studies found higher discontinuation rates related 
to younger age (Tweya et al., 2014) or lower maternal educational level (Gourlay, 
Birdthistle, Mburu, Iorpenda, & Wringe, 2013)  which were associated in our analysis only 
with non-significant higher odds possibly due to a small sample size. We also observed an 
over 2.7 times higher, non-significant odd of treatment discontinuation in women who 
initiated ART during breastfeeding as compared to those starting during pregnancy. This 
could be associated with waning maternal concerns for infant HIV transmission 
postpartum and more attention tends towards the care of the baby, requiring focused 
counselling support (Clouse et al., 2014). In Malawi women starting ART at pregnancy 
were more likely to be LTFU than those who started ART while breastfeeding. However, 
the authors indicated that this improved retention could have been due to the additional 
motivation in terms of food supplements that were given to breastfeeding women for 
their children from 6 to 24 months which was not the case in the present study (Tweya et 
al., 2014). There was however, no difference in retention-in-care between women 
initiating lifelong ART with a lower CD4+ T-cell count when compared to those initiating 
treatment with a higher CD4+ T-cell count. We thus failed to reject our null hypothesis. 
Other studies have produced conflicting results. In a study by Grimsrud and colleagues in 
South Africa (Grimsrud et al., 2016) they found a higher rate of LTFU for women initiating 
treatment with a higher CD4+ T-cell count. Yet in another study still from South Africa, 
Clouse and colleagues found a lower rate of LTFU among patients initiating treatment with 
a higher CD4+ T-cell count (Clouse et al., 2013).  These two studies had different cut off 
values defining higher CD4+ T-cell count (≥300 cells/µL and 201-350 cells/µL respectively) 
which were completely different from our cut off of CD4+ T-cell count was > 350 cells/µL. 
Our small sample size could have also been responsible for the lack of association as we 
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thought women with higher CD4+ T-cells because they are not sick may be more likely to 
drop out of care compared with those initiating treatment for their own health.   
 
Of the women who discontinued treatment, 36 (55.4%) intentionally decided to stop ART 
leaving their infants at high risk of HIV infection. Status denial, stigma and discrimination 
(52.9%) were top among reasons for stopping ART followed by religious reasons (25.0%) 
and lack of transport fare (11.1%) to attend clinics. Lack of transport to facility has been 
frequently reported as a reason for discontinuing treatment. Our study was limited to the 
Kumba health district to reduce the difficulty of travelling by bad roads during the rainy 
season.  Decentralisation of HIV services has been reported to be associated with 
improved retention by reducing transportation cost, travel time and clinic waiting time 
among other benefits. A study in Malawi reported a higher LTFU rate at hospital (9.9%) 
than at rural health centres (1.5%), such that the use of rural centres resulted in a 77% 
reduction in risk of attrition (Massaquoi et al., 2009). WHO now strongly advises national 
programmes to decentralise HIV and AIDS care and treatment programmes to improve 
retention-in-care (WHO, 2016). 
 
Furthermore, women who were declared LTFU could often not be traced because of 
incorrect contacts or contact details that were changed without informing the facility 
staff. This as well might be attributed to stigma and discrimination, or poor staff 
treatment at the clinic as reported in a South African study (Clouse et al., 2014). Stigma 
and fear of status disclosure to partners, family or community members are the most 
frequently reported barriers to ART or PMTCT procedures in sub-Saharan Africa (Gourlay 
et al., 2013; Jacobi et al., 2013) . Counselling messages to newly diagnosed HIV-positive 
women should include normalizing language to reduce stigma and  social desirability bias 
(Simoni et al., 2006; Vinten, 1998), so that women could provide correct location details 
and phone numbers for subsequent tracing. Also staff should on a regular basis remember 
to update clients’ contacts. This could be done annually to be sure they are still in 
possession of the right addresses and contacts of their clients. 
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Other tracing outcomes provided valuable information which could be used to further 
strengthen retention-in-care. Silent self-transfers to other health facilities were very 
common among women in this study that could have been as well related to stigma and 
discrimination. There is an inherent need to improve communication between ART clinics 
and Option B+ sites for better linkages and documentation of transferred-out cases, 
avoiding misclassification that could underestimate retention rates.   
5.3 Adherence to ART treatment and virologic outcomes 
Retention-in-care has for long in many circumstances been used as a surrogate measure 
of adherence, but retention as is often defined gives just a snapshot of the patient’s 
attendance at the clinic which may not necessarily reflect adequate medication taking. 
More so retention measured at a given time point fails to register missed visits thus failing 
to capture patterns of attendance and care received by mothers and children (N. C. Rollins 
et al., 2014). Adherence to treatment and care is therefore very important if we must 
adequately evaluate the success of the PMTCT programme. Apart from factors preventing 
adherence in non-pregnant adults, the nausea and vomiting of pregnancy and possible 
side effects of the drugs on the foetus are additional factors that makes adherence in 
pregnancy a challenge. Post-delivery attention is turned towards the baby and in most 
circumstances the mother turns to pay less attention to her own health and medications 
thus compromising adherence postpartum (Clouse et al., 2014).  
The few studies in Cameroon that have assessed adherence to ART have mainly focussed 
on men and non-pregnant women and have used one or the other measures like self-
reports, pill counts or pharmacy records with variable results (Mahy et al., 2011; Mbopi-
Kéou et al., 2012; Mbuagbaw et al., 2012). Using just one or the other of these measures 
have been shown to be without limitations either under or overestimating adherence (Liu 
et al., 2001; Steel et al., 2007). We therefore, measured adherence for women initiated on 
Option B+ in Kumba health district and retained in care, Cameroon using a composite 
adherence score. To the best of our knowledge this is the first study in Cameroon to 
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measure adherence for pregnant and breastfeeding women using a composite adherence 
score. Understanding the implication of Option B+ which requires healthy women being 
started on lifelong ART we hypothesized that women with a lower CD4+ T-cell count at 
treatment initiation will better adhere to treatment since they are considered taking it for 
their own health than those who were initiated on treatment with a higher CD4+ T-cell 
count.  
Among our study participants at 6 months 59.0% reported perfect adherence and 62.7 % 
at 12 months this is much lower than that reported by Hass and colleagues in Malawi 
(Haas, Msukwa, et al., 2016). This difference is likely due to the approach used to measure 
adherence. The Malawian study used pharmacy records alone to measure adherence 
unlike in our study where adherence was measured with a composite score combing three 
different measures.  
The different adherence measures employed were all correlated with each other and all 
were significantly correlated to the composite adherence score with a Spearman 
correlation ranging from 0.36 to 0.83 (p < 0.001 for all comparisms). VAS however, 
showed the strongest correlation with CAS. Some authors have argued that the use of CAS 
for measuring adherence may be cumbersome in clinical settings (Simoni et al., 2006). As 
shown by our results like that reported by Giordano  and colleagues (Giordano et al., 
2004) a simple easy to use tool as the VAS could be conveniently used in clinical  and 
research settings and will still produce results similar to the CAS. On the other hand, 
several studies have shown that with non-nucleoside reverse transcriptase inhibitors and 
boosted protease inhibitors (PIs) containing regimens you do not need perfect adherence 
for virologic suppression (Bangsberg, 2006; Maggiolo et al., 2005; Jean B Nachega et al., 
2007).  
After validating the adherence measured with virologic outcome, we went ahead and 
classified adherence into two categories as good or poor and overall, 88.6% of women 
reported good adherence to Option B+ treatment protocol at 12 months post ART 
initiation. This was comparable (87.0%) with that of the study of adherence with Option 
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B+ carried out in Ethiopia (Ebuy et al., 2014) and from western Kenya (89.0%)(Ayuo et al., 
2013) but slightly higher than adherence reported for the same target group from Nnewi 
in Nigeria (78.3%) (Igwegbe, Ugboaja, & Nwajiaku, 2010). This difference could be 
explained by the PMTCT options used. The study from Nigeria was conducted in the era of 
Option A but this study and those from Ethiopia and Kenya were from women initiating 
Option B+. 
The main predictors of poor adherence to lifelong ART for women included in this study 
were younger age at treatment initiation, lower level of education, employment in the 
informal sector and belonging to a Pentecostal church.  
Younger age and lower education level have been reported as predictors of treatment 
discontinuation which could indirectly affect adherence to treatment (Tenthani et al., 
2014; Tweya et al., 2014). A study in Nigeria found the contrary with older rather than 
younger age being a predictor of non-adherence (Igwegbe et al., 2010). This discrepancy 
in the results may well be due to the way the data was collected and presented. In this 
study and the studies from Malawi age was categorised into two while the Nigerian study 
had three age categories which differed greatly from ours.  
Employees in the informal sector have to work extra hard to maintain their jobs or 
generate their own income thus leaving them with little time to concentrate on their 
health and treatment unlike employees in the formal sector who in this study were mainly 
public civil servants or those unemployed. Studies have shown that conflict with work 
commitment and the difficulty of disclosing ones status to an employer affected ARV 
adherence in women on Option B+ (Clouse et al., 2014). Flexible clinics opening hours like 
in the evenings or on Saturdays when most workers are free and do not need to take time 
or a day off just to attend clinic could improve adherence on treatment for most of these 
women. 
Pentecostal preaching with its emphasis on salvation and strong social cohesion helps to  
prevents their members from engaging in as much extra- and pre-marital sex as other 
Christian denominations, thus protecting against HIV transmission (Garner, 2000). 
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However, Zou et al., in 2009 noted, “At community level, religious organisations are 
influential social networks that have the power to support or stigmatize PLHIV, promote 
or impede HIV education, and endorse or reject medical treatment of HIV” (Zou et al., 
2009). In this study belonging to a Pentecostal church was a strong predictor of poor 
adherence to treatment. This is supported by our findings that most of the women who 
stopped their treatment for religious reasons did not find any reason for returning to care 
and claimed they will be healed by their faith.  
There was no difference in adherence between women initiating treatment with a lower 
CD4+ T-cell count compared to those with a higher CD4+ T-cell count; we thus failed to 
reject our null hypothesis.  
Like many studies from  sub-Saharan African countries many participants in this study 
cited forgetfulness, being away from home (J. B. Nachega et al., 2004) and lack of 
transport to the health facility and side effects of drugs as possible reasons for missing 
doses of their ARVs (Ayuo et al., 2013; Ekama et al., 2012; Igwegbe et al., 2010; Tweya et 
al., 2014). This information generated from the self-report interviews can be very useful 
during adherence counselling of HIV-positive pregnant and breastfeeding women. On the 
other hand our participants also indicated that reminder aids like cell phones, clock alarms 
and reminder from family members helped improve their adherence. However, others 
women claimed that medication taking have become a routine for them so they do not 
need reminders. The high frequency of routine may be because of the women best 
intention to continue taking their medication or methodological reasons such as social 
desirability concerns.  Many studies have shown that the use of cell phones and other 
reminders gadgets can greatly improve adherence (Hardy et al., 2011; Mbuagbaw, 2014; 
Reynolds et al., 2007). The role of family members like husbands, sisters and mothers as 
treatment buddies emphasised the need to continuously counsel and support HIV-positive 
women to disclose their status to significant orders in order to get the maximum benefits 
of disclosure (Ebuy et al., 2014; Igwegbe et al., 2010). HIV status disclosure should remain 
voluntary as this could be accompanied by partner violence (Colombini, James, & Ndwiga, 
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2016; Ezechi et al., 2009).  Instead women who decline to disclose should be counselled 
and encouraged until they feel safe to disclose. 
Viral suppression in the study participants retained in care at 12 months was very good. A 
total of 92.7% (153/165) of women achieved virological suppression (<1,000copies/µL) as 
per WHO definition (WHO, 2013). Poor adherence to antiretroviral drugs has been 
reported to be the major challenge to achieving this main goal of antiretroviral therapy 
(Maggiolo et al., 2005).  Adherence at 12 months after ART initiation significantly 
predicted virologic outcome with patients reporting poor adherence more likely not to 
achieve adequate virologic suppression. The virologic-suppression rates were similar or 
superior to those in cohorts of non-pregnant adults in Africa (El-Khatib et al., 2011; Haas, 
Msukwa, et al., 2016), suggesting that virologic suppression is achievable both in 
pregnancy or breastfeeding. High virologic suppression was reflected by the low rate of 
mother-to-child transmission of 1.8% at 6–8 weeks in this study. Most of the women in 
this study started ART in the 1st and 2nd trimesters of pregnancy (73.3%). We believe that 
good adherence overall and initiation of ART early in pregnancy in most women 
accounted for the excellent suppression rates and low early MTCT rate. The initiation of 
ART before 30 weeks’ gestation could improve virologic suppression at delivery and may 
have reduced the risk of in utero transmission. 
5.4 Infant and children HIV-free survival 
Option B+ was conceived with the vision of increasing ART coverage for pregnant and 
breastfeeding women and eliminating new cases of HIV infection among children. The rate 
of retention-in-care was good (81.1%) at 12 months and 83.6% of the infants’ had their 
DBS samples for DNA-PCR collected between 5 and 8 weeks of delivery thus respecting 
the national protocol (CNLS, 2015). These results were superior to the 80% between 5 and 
13 weeks obtained by Pérez and colleagues in Thyolo, Malawi (Martínez Pérez et al., 
2014). This difference could be solely explained by the fact that we were in a pilot project 
with a lot more resources available for patient tracking why the result from Thyolo were 
from routine data collected by health facilities.  The mean PCR turnaround time in this 
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study was 6 weeks showing a marked improvement from what has been previously 
reported in national reports in the pre-Option B+ era (CNLS, 2014). The early HIV 
transmission  to infants of 1.8% in this study showed a significant dropped in value when 
compared to the national early transmission rate of 5.2% published by UNAIDS in its 2016 
on the fast track report (UNAIDS, 2016a). It was also much lower (3.6%) than that 
reported in Malawi (Herce et al., 2015). The national rate of 5.2% early transmission 
included sites that were still practicing option A in the country by the end of 2015. We 
found a very low final MTCT rate (2.6%) when compared to the national rate of 12.6% 
reported by UNAIDS in its 2016 report (UNAIDS, 2016a). Though this rate was expected to 
be lower in this pilot study but due to the fact that administratively the database was 
closed when just about half of the children born in the cohort had a complete follow-up 
this could not be conclusive. A much longer follow up will be required to confirm this 
finding.  
5.5 Pregnancy outcomes 
Some pregnancy outcomes like abortions, stillbirths, low birth weights and premature 
deliveries were observed in our cohort. In a meta-analysis, HIV infected women were at 
higher risk of having a low birth weight infant or a preterm delivery infant compared with 
uninfected women (Xiao et al., 2015). However, since we did not have any comparative 
group and the timing of these events were not carefully planned with treatment initiation, 
the association with the treatment protocol or HIV infection status of the women could 
not be established. More work is needed to confirm these findings and to explore specific 
aetiology pathways by which such effects may operate. A study in the United States rather 
confirms that the increasing use of ART during pregnancy has rather resulted in a decline 
in the rate of low birth weight and prematurity (Schulte, Dominguez, Sukalac, Bohannon, 
& Fowler, 2007). Another study showed that PI containing regimens were more associated 
with preterm birth but there were no differences in rates of low birth weight and stillbirth, 
regardless of therapy (Cotter, Garcia, Duthely, Luke, & O’Sullivan, 2006). Contrary to 
reports that preterm delivery and low birth weight increased the risk of MTCT of HIV 
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(Landesman et al., 1996), we did not find any association between birth weight, 
gestational age at delivery and HIV infection in children. This lack of association could also 
be explained by our small sample size. 
5.6 Study limitations 
Limitations for the generalizability of our results are mainly study procedure related. This 
includes prospective data collection within a newly launched pilot activity, available 
tracing information and optimized tracing procedures for all study participants, and 
treatment counselling possibly beyond the usual routine procedures. However, though 
our results reflect what has been reported in many other studies the following cautions 
are necessary in the implementation of these findings.  As we considered LTFU as missed 
retentions there is a possibility of misclassification which could have affected our 
retention rates. Also our adherence to Option B+ by women in this cohort might have 
been overestimated as early dropouts were excluded from the analysis. The viral 
suppression rate was very high and could have been overestimated as only women 
retained in care had viral load testing. The small sample size could explain the lack of 
significant association between many socio-demographic and clinical characteristics with 
treatment discontinuation and adherence to ART treatment. Since our participants were 
recruited while at clinic visits the good retention-in-care and high adherence to treatment 
for women retained in care may not be extrapolated to the entire population of women 
expected at ANC and IWC. However, our results are consistent with other studies of HIV-
positive women receiving PMTCT Option B+ services in other sub-Saharan African settings. 
Despite these limitations, we believe that the study findings are useful to inform 
implementation of PMTCT Option B+ in Cameroon and other comparable settings. 
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6. Conclusions and implications 
In conclusion we observed promising 12 months retention-in-care and adherence to 
Option B+ in pregnant or breastfeeding women initiating Option B+ in Kumba health 
district comparable to other African reports. Retention rates were lowest at small health 
facilities with a high staff turnover and multiple task assignments, while adherence was 
poor for younger women, women with low level of education, those employed in the 
informal sector and those attending Pentecostal churches. Our findings suggest an urgent 
need to expand the Option B+ related human resources and also to reinforce counselling 
messages for younger and less educated women initiating Option B+. Adequate task 
shifting, reduction of staff mobility, improved staff working conditions and motivation, 
implying improved quality of post-test counselling may improve retention and adherence 
to therapy. Furthermore, enhancing community interventions, decentralization of service 
delivery, HIV workplace policies, defaulters tracking and reducing stigma and religious 
beliefs are measures that may improve retention-in-care and adherence to lifelong 
therapy. More studies are needed with  larger cohorts and a longer follow up time in 
Cameroon to better assess treatment outcomes like final HIV transmission rates for a 
comprehensive evaluation of the impact of Option B+ in Cameroon. 
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8. Annexes 
Annex 1: Questionnaire 
Data Collection Form (Version 2.0, 1st Feb .2014) 
 
Centre Code |___|    Patient Identification N° 
|___|___|___|___|___| 
Study: ARV Adherence and retention cohort: HIV-positive pregnant women on option B+ 
This study seeks to find out how well HIV-positive pregnant women on antiretroviral medicines 
(ARV) take their drugs. Please you are therefore, invited to answer these questions as honestly as 
you can to express your own experiences. 
You do not have to answer if you do not want to but completing as much of the questionnaire as 
you can would help us to better manage any problems that you may be facing with taking your 
medication. 
Date of enrolment: [__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy) 
 
VISIT I 
 I. a). Socio-demographic information of participant  
No Question Response (Enter the number corresponding to the 
correct response in the check box) 
Skip to 
Q101 Physical Address Quarter............................................................................ 
Telephone Number......................................................... 
Telephone number of contact Person.............................. 
 
Q102 Date of Birth [__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy)  
Q103 Age (years) [__|__]  
Q104 Marital Status [__] 
1= Single,  2= Married,   3= Widow,   4=Divorced,  
5=Concubine ("come we stay") 
If 1,3,4, 
5 go to 
Q106 
Q105 Form of marriage  [__] 
1=Monogamy,    2=Polygamy,   
 
Q106 Highest Level of 
education 
[__] 
0=None,   1= Completed primary,  2=Completed 
Secondary, 3= Completed high school,   4=University 
and higher  
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Q107 Division of origin ........................................................................................  
Q108 Religious affiliation [__] 
1=Catholic,  2=Presbyterian,  3= Baptist,  4=Pentecostal,    
5= Moslem, 
6=Others(Specify)........................................................... 
 
Q109 Occupation [__] 
1=Unemployed,   2=Housewife;  3= Farmer,   
4=Business, 5= Pupil/Student;  6= Staff employed in the 
civil sector, 7=  Staff employed in the private sector,  8= 
others (Specify)............................................. 
 
Q110 Do you have children? [__] 
0=No    1=Yes 
If 0 go 
to Q113 
Q111 Number of children [__|__]  
Q112 Age of last child (years) [__|__]  
 
I. b). Information on current pregnancy  
Q113 Date of ANC visit [__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy)  
Q114 LMP [__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy)  
Q115 Gestational Age  [__|__]Weeks  
Q116 Gravida [__|__]  
Q117 Parity [__|__]  
 
I. c). Current HIV status (With present pregnancy) 
Q118 Date of HIV diagnosis [__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy)  
Q119 HIV test result (type) [__]       
1=HIV type I,   2=HIV type 2,  3= HIV type 1 & 2,   9= 
Unknown 
 
Q120 WHO clinical stage at 
diagnosis 
[__] 
0=WHO stage I,   1=WHO stage II,   2=WHO stage III,   
3= WHO stage IV,   9= Unknown/Not sure  
 
Q121 Date of last CD4 Count [__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy),     
 [__] Not available 
 
Q122 Last CD4 count [__|__|__|__]cells per mL,    [__]   Not available  
Q123 Creatinine  level [__|__|__|__]mg/dL,            [__]   Not available  
Q124 Hb level [__|__ ]. [__] g/dl  
Q125 Weight  [__|__|_ ]. [__] kg  
Q126 Height  [__|__ ]. [__] m  
Q127 Ever used ARV before [__]       
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0=No            1=Yes 
Q128 Present  ARV regimen     [__] 
1= AZT/3TC/NVP 
2= AZT/3TC/EFV 
3= TDF/3TC/NVP 
4= TDF/3TC/EFV 
5= Others (specify).......................................................... 
 
Q129 Date of initiation on this 
treatment 
[__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy)  
Q130 Place of ARV initiation [__]                   
1= ANC,  2= Labour room,  3=Postpartum,   4=IWC,       
5=HIV treatment centre 
 
Q131 On Cotrimoxazole 
prophylaxis 
 [__] 
0=No         1= Yes 
 
Q132 Partner tested  for HIV [__] 
0=No         1=Yes 
 
Q133 Partner HIV status [__]     
0=Negative,   1=Positive,  2=Indeterminate,  
9= Unknown 
 
Q134 Partner's HIV results 
(type) 
[__]  
1=HIV type I,   2=HIV type 2,  3= HIV type 1 & 2,  
 9= Unknown 
 
Q135 Partner's on ARV [__] 
0=No ,  1=Yes,   3=Don't know 
 
 
Visit done by: ______________  
Signature: _____________ Date: |__|__|/|__|__|__|/|__|__|__|__| 
 
Checked by:________________ Signature: _____________ Date: |__|__|/|__|__|__|/|__|__|__|__| 
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VISIT II. 
LABOUR AND DELIVERY  
No Question Response ( Enter the number corresponding to the 
correct response in the check box ) 
Skip to 
Q201 Date of delivery [__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy)  
Q202 Place of delivery [__] 
1=Health facility,    2=Home,  
 3= Others (specify).................................................. 
If 2,3 go 
to Q204 
Q203 Delivery conducted by  [__] 
1= Doctor,   2=Nurse,   3=Midwife ,  
4= Others (specify)................................................... 
9=  Unknown 
 
Q204 Home delivery 
conducted by 
[__] 
1.= Relative,  2.= Friend,  3=Neighbour,  
4= Nurse/midwife   5=Traditional Birth Attendant   
 
Q205 Mode of delivery  [__] 
1=Vaginal,  2= Caesarean Section ,  3= Forceps,   
4= Ventouse  
 
Q206 Gestational age at 
delivery 
 
[__|__] Weeks 
 
Q207 Birth weight of baby [__|__|__|__] g  
Q208 APGAR Score (5min) [__|__ ]  
Q209 Sex [__] 
1= Male,   2= Female 
 
Q210 Premature rupture of 
membranes 
[__] 
0=No       1= Yes 
 
Q211 Episiotomy [__] 
0=No       1= Yes 
 
Q212 Multiple delivery [__] 
0=No       1= Yes 
 
Q213 Baby resuscitation after 
delivery 
[__] 
0=No       1= Yes 
 
Q214 Other birth  outcomes [__] 
1=Still birth, 2=Infant death after delivery, 3= birth 
defect, 4=Others (Specify)........................................ 
 
Q215 Mother's viral load [__|__|__|__|__|__|__] copies 
[__]   Not available 
 
 
Visit done by: ______________ 
 
Signature: ________________ Date: |__|__|/|__|__|__|/|__|__|__|__| 
Checked by:________________ Signature: ________________ Date: |__|__|/|__|__|__|/|__|__|__|__| 
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VISIT III. 
III. a.  6-8 WEEK POSTPARTUM FOLLW-UP / EID  
No Question Response (Enter the number corresponding to the 
correct response in the check box ) 
Skip to 
Q301 Date of postpartum visit [__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy)  
Q302 Baby Feeding option [__] 
1= Exclusive breast feeding,  2= Exclusive artificial 
feeding,  3=Mixed feeding,   
4= Others (specify)....................................................... 
 
Q303 Is baby on Nevirapine [__] 
0= No    1= Yes 
 
Q304 Date of initiation on 
Nevirapine 
[__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy)  
Q305 Baby initiated on 
Cotrimoxazole 
prophylaxis 
[__] 
0= No    1= Yes 
 
Q306 PCR1collected [__] 
0= No    1= Yes 
 
Q307 Date of collection of  
baby PCR1 
[__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy)  
[__]  Not available 
 
Q308 Date of delivery of 
results PCR1  
[__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy) 
[__]  Not available 
 
Q309 Baby PCR1 results   [__] 
0= Negative, 1= Positive, 2=Indeterminate 
If 0,2 
go to 
Q313 
Q310 Baby started on ARV [__] 
0= No    1= Yes 
 
 
 
Q311 ARV  regimen [__] 
1= AZT/3TC/NVP 
2= Triomune Baby/Junior 
3= AZT/3TC/LPV/r 
4= Others (specify)........................................................ 
 
Q312 Date of initiation on ARV [__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy) 
 
 
Q313 PCR2 collected [__] 
0= No    1= Yes 
 
Q314 Date of collection PCR2 [__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy) 
[__]  Not available 
 
Q315 PCR2 results  [__] 
0=Negative, 1=Positive,  2= Indeterminate 
 
Q316 Date of result PCR 2 [__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy) 
[__]  Not available 
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III. b.  MOTHER'S TRACING INFORMATION 
Q317 Attended visit [__] 
0= No    1= Yes 
 
Q318 Traced to attend clinic 
visit 
[__] 
1=Traced by phone call and came to clinic,  2=Traced 
through home visit and came to clinic,  3= Not 
traceable,  4= Others (specific)...................................... 
 
Q319 Date of clinic 
attendance after tracing 
[__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy) 
 
[__]  Not available 
 
Q320 Reasons for not 
attending post-delivery 
visits 
[__] 
1 = Lack of money,  2= Sick/disease,  3 = Afraid of 
stigmatization,  4= Do not like the PMTCT 
service/interventions,  5= Fear of family, relatives and 
community,  6 = Religious believes. 
 
Q321 If did not return for 
clinic what is mother 
status 
[__] 
1=Transfer out,    2=Lost to follow-up,   3= Death, 
9= Unknown 
 
 
 
Visit done by: _________________ 
 
Signature: ___________ Date: |__|__|/|__|__|__|/|__|__|__|__| 
 
 
Checked by:___________________ Signature: ____________ Date: |__|__|/|__|__|__|/|__|__|__|__|
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VISIT IV. 
 SIX MONTH AFTER ARV INITIATION  
IV. a) Follow-up information 
No Question Response (Enter the number corresponding to the 
correct response in the check box ) 
Skip to 
Q401 Date of visit [__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy)  
Q402 CD4 count [__|__|__|__]cells per mL 
[__]   Not available 
 
Q403 Viral load [__|__|__|__|__|__|__] copies 
[__]   Not available 
 
Q404 Current ARV regimen [__] 
1= AZT/3TC/NVP 
2= AZT/3TC/EFV 
3= TDF/3TC/NVP 
4= TDF/3TC/EFV 
5= Others (specify)........................................................ 
 
Q405 Side effects of  ARV  [__] 
0=None,  1=Skin rash,  2=Jaundice,   3= Dizziness  
4= Night mares  
5= Others (specify)........................................................ 
 
Q406 Has ARV been switched 
or substituted  during 
last 6months 
[__]     
0= No, 1=Yes 
 
Q407 Date of ARV regimen 
change 
[__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy),  
[__] Not available 
 
Q408 Reasons for switching or 
substitution  
[__] 
1= Severe side effects,    2= Stock out of drugs,   
3= Treatment failure,     9= Unknown 
If 3 go to 
Q410 
Q409 In case of substitution 
what is the new ARV 
regimen 
[__] 
1= AZT/3TC/NVP 
2= AZT/3TC/EFV 
3= TDF/3TC/NVP 
4= TDF/3TC/EFV 
5= Others (specify)................................................ 
 
Q410 In case of treatment 
failure what is the 2nd 
Line regimen 
[__] 
1= AZT/3TC/LPV/r 
2= AZT/3TC/ATV/r 
3= TDF/3TC/LPV/r 
4= TDF/3TC/ATV/r 
5= Others (specify)................................................... 
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IV. b) Child's Information 
Q411 Baby status [__] 
1= Alive,  2=Death, 9 = Unknown 
If 2 go to 
Q417 
Q412 Baby still  on NVP syrup  [__] 
0=No,   1=Yes 
 
Q413 Baby on ARV [__] 
0=No,   1=Yes 
 
Q414 Baby on Cotrimoxazole [__] 
0=No,   1=Yes 
 
Q415 Baby still breastfeeding [__] 
0=No,   1=Yes 
 
Q416 If not breastfeeding  
date of weaning  
[__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy), 
[__] Not available 
 
Q417 If death,  date of death [__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy), 
[__] Not available 
 
 
IV. c) Adherence information 
“I understand that most people taking antiretroviral medication (anti-HIV drugs) find it very 
difficult to take their medication regularly and may miss some doses. So I will not be surprised if 
you have had this happen to you. It is important for me to understand how you are really doing 
with your medicine. Don’t worry about telling me if you don’t always take all your doses. I need to 
know what is really happening, not what you think I want to hear”. 
 
1) Pharmacy refills   
Q417 Number of ARV refill 
appointments respected 
in the last 6 months 
 [__] 
1= 1refill,    2=2 refills,      3= 3 refills,      4=4 refills, 
5=5 refills,     6=6 refills 
 
 
2) Self-Reported Adherence  
Q418 Do you sometimes find 
it difficult to remember 
to take your medicine? 
[__] 
0=No,   1=Yes 
 
Q419 When you feel better, 
do you sometimes stop 
taking your medicine? 
[__] 
0=No,   1=Yes 
 
Q420 Thinking back over the 
past 4 days, have you 
missed any of your 
doses? 
[__] 
0=No,   1=Yes 
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Q421 Sometimes if you feel 
worse when you take 
the medicine, do you 
stop talking it? 
[__] 
0=No,   1=Yes 
 
 
 
 
Q422 What causes you to miss 
some doses of your 
drug? 
...................................................................................
................................................................................... 
 
Q423 What helps you 
remember to take your 
drugs? 
 
...................................................................................
................................................................................... 
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4) Q424: Visual Analogue Scale (VAS) 
“Now I would like to ask you to estimate how much of your prescribed ARV you took in the last 
month. A mark at the left end where there is a number zero means you have taken no 
medications. A mark in the middle means you have taken about half of your medications. A mark 
on the right end where you can see the number ten means you have taken every single dose of 
your medications. Please put a mark on this line somewhere between zero and 10 to describe 
your best guess about how much of your prescribed medication you took in the last month”.  
 
 
Composite Adherence Assessment (To be determined by supervisor) 
Adherence measure SCORE 
Pharmacy Refill Had 6 refills (3) Missed 1 refill (2) Missed 2 or more refills (1) 
Self-Report No to all Questions (3) Yes to 1 question (2) Yes to 2 or more questions (1) 
VAS 90%  or more (3) 70 & 80% (2) Less than 70% (1) 
Overall Adherence High Moderate Low 
 
Adherence tool Score 
Medication refill 3 3 3 3 3 2 3 2 2 1 
Self-Report 3 3 3 2 2 2 1 2 1 1 
VAS 3 2 1 2 1 2 1 1 1 1 
Total score 9 8 7 7 6 6 5 5 4 3 
CAS High Moderate low 
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Visit done by: ____________________ 
 
Signature: ___________  Date: |__|__|/|__|__|__|/|__|__|__|__| 
 
Checked by:_____________________ Signature: ___________  Date: |__|__|/|__|__|__|/|__|__|__|__| 
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VISIT V. 
 TWELVE MONTH AFTER ARV INITIATION  
V. a) Follow-up information 
No Question Response (Enter the number corresponding to the 
correct response in the check box ) 
Skip to 
Q501 Date of visit [__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy)  
Q502 CD4 count [__|__|__|__]cells per mL 
[__]   Not available 
 
Q503 Viral load [__|__|__|__|__|__|__] copies 
[__]   Not available 
 
Q504 Current ARV regimen [__] 
1= AZT/3TC/NVP 
2= AZT/3TC/EFV 
3= TDF/3TC/NVP 
4= TDF/3TC/EFV 
5= Others (specify)........................................................ 
 
Q505 Side effects of  ARV  [__] 
0=None,  1=Skin rash,  2=Jaundice,   3= Dizziness  
4= Night mares  
5= Others (specify)........................................................ 
 
Q506 Has ARV been switched 
or substituted  during 
last 6months 
[__]     
0= No, 1=Yes 
 
Q507 Date of ARV regimen 
change 
[__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy),  
[__] Not available 
 
Q508 Reasons for switching or 
substitution  
[__] 
1= Severe side effects,    2= Stock out of drugs,   
3= Treatment failure,     9= Unknown 
If 3 go 
to Q510 
Q509 In case of substitution 
what is the new ARV 
regimen 
[__] 
1= AZT/3TC/NVP 
2= AZT/3TC/EFV 
3= TDF/3TC/NVP 
4= TDF/3TC/EFV 
5= Others (specify)................................................ 
 
Q510 In case of treatment 
failure what is the 2nd 
Line regimen 
[__] 
1= AZT/3TC/LPV/r 
2= AZT/3TC/ATV/r 
3= TDF/3TC/LPV/r 
4= TDF/3TC/ATV/r 
5= Others (specify)................................................... 
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IV. b) Child's Information 
Q511 Baby status [__] 
1= Alive,  2=Death, 9 = Unknown 
If 2 go 
to Q517 
Q512 Baby still  on NVP syrup  [__] 
0=No,   1=Yes 
 
Q513 Baby on ARV [__] 
0=No,   1=Yes 
 
Q514 Baby on Cotrimoxazole [__] 
0=No,   1=Yes 
 
Q515 Baby still breastfeeding [__] 
0=No,   1=Yes 
 
Q516 If not breastfeeding  
date of weaning  
[__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy), 
[__] Not available 
 
Q517 If death,  date of death [__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy), 
[__] Not available 
 
 
V. c) Adherence information 
“I understand that most people taking antiretroviral medication (anti-HIV drugs) find it very 
difficult to take their medication regularly and may miss some doses. So I will not be surprised if 
you have had this happen to you. It is important for me to understand how you are really doing 
with your medicine. Don’t worry about telling me if you don’t always take all your doses. I need to 
know what is really happening, not what you think I want to hear”. 
 
1) Pharmacy refills   
Q517 Number of ARV refill 
appointments respected 
in the last 6 months 
 [__] 
1= 1refill,    2=2 refills,      3= 3 refills,      4=4 refills, 5=5 
refills,     6=6 refills 
 
 
2) Self-Reported Adherence  
Q518 Do you sometimes find 
it difficult to remember 
to take your medicine? 
[__] 
0=No,   1=Yes 
 
Q519 When you feel better, 
do you sometimes stop 
taking your medicine? 
[__] 
0=No,   1=Yes 
 
Q520 Thinking back over the 
past 4 days, have you 
missed any of your 
doses? 
[__] 
0=No,   1=Yes 
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Q521 Sometimes if you feel 
worse when you take 
the medicine, do you 
stop talking it? 
[__] 
0=No,   1=Yes 
 
Q522 What causes you to miss 
some doses of your 
drug? 
...........................................................................................
.................................................................................. 
 
Q523 What helps you 
remember to take your 
drugs? 
 
...........................................................................................
................................................................................... 
 
 
4) Q524:  Visual Analogue Scale (VAS) 
“Now I would like to ask you to estimate how much of your prescribed ART you took in the last 
month. A mark at the left end where there is a number zero means you have taken no 
medications. A mark in the middle means you have taken about half of your medications. A mark 
on the right end where you can see the number ten means you have taken every single dose of 
your medications. Please put a mark on this line somewhere between zero and 10 to describe 
your best guess about how much of your prescribed you took in the last month”.  
 
Composite Adherence Assessment (To be determined by supervisor) 
Adherence measure SCORE 
Pharmacy Refill Had 6 refills (3) Missed 1 refill (2) Missed 2 or more refills (1) 
Self-Report No to all Questions (3) Yes to 1 question (2) Yes to 2 or more questions (1) 
VAS 90%  or more (3) 70 & 80% (2) Less than 70% (1) 
Overall Adherence High Moderate Low 
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Adherence measure SCORE 
Pharmacy Refill 3 3 3 3 3 2 2 2 1 
Self-Report 3 3 3 2 2 2 2 1 1 
VAS 3 2 1 2 1 2 1 1 1 
Total score 9 8 7 7 6 6 5 4 3 
Overall Adherence (CAS) High Moderate low 
 
Visit done by: 
_____________________ 
 
Signature: ________________ 
Date: |__|__|/|__|__|__|/|__|__  
 
Checked 
by:_______________________ Signature: ________________ Date: |__|__|/|__|__|__|/|__|__  
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VISIT VI. 
FINAL HIV STATUS OF INFANT  
Q701 Date of infant's HIV  
rapid test 
[__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy) 
 
[__]  Not Available 
 
 
Q702 Result of infant's HIV 
rapid test 
[__] 
0=Negative,  1=Positive,  2= Indeterminate, 9=Unknown 
 
 
 
Checked by:________________ Signature: _____________ Date: |__|__|/|__|__|__|/|__|__|__|__| 
Visit done by: _______________ 
 
Signature: _____________ Date: |__|__|/|__|__|__|/|__|__|__|__| 
 
PI' s Final verification 
Name_____________________________________________________ 
Signature__________________________________________________ 
Date: |__|__|/|__|__|__|/|__|__|__|__| 
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Study Case Report Form (Version 1.0, 1st Feb. 2014) 
Patient Status At Exit From Study 
       
 Centre Code |___|                                               Patient Identification N° 
|___|___|___|___| 
 
This form is filled out at the last visit or when a patient is not more coming for her 
appointments and efforts to trace her have failed. 
 
Date of exit (completion or termination) : [__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy) 
 
What is the Mother's Status? 
[__]      Patient completed follow-up 
[__]      Early termination 
 
Reasons for early termination. 
01 Withdrawn informed consent [__] 
02 Moved out of study area (Transferred out) [__] 
03 Lost to follow-up [__] 
04 Death, Date. [__|__] - [__|__] - [__|__|__|__] (dd/mm/yyyy) [__] 
05 Stopped treatment [__] 
06 Reasons for stopping: Religion [_1_], S & D[_2_], Status denial [_3_],Transport [_4_],  [__] 
07 Others (specify): 
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Annex 2: Visual Analogue Scale (VAS) 
“Now I would like to ask you to estimate how much of your prescribed ARV you took in 
the last month. A mark at the left end where there is a number ZERO (0) means you have 
taken no medications. A mark in the MIDDLE (5) means you have taken about half of 
your medications. A mark on the right end where you can see the number TEN (10) 
means you have taken every single dose of your medications. Please put a mark on this 
line somewhere between ZERO and TEN to describe your best guess about how much of 
your prescribed medication you took in the last month”. 
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Annex 5: Statement on Pre-release and contribution 
The currently presented thesis entitled “Retention-in-Care, Adherence and Treatment 
outcomes in a cohort of HIV-positive pregnant and breastfeeding women enrolled in a 
pilot project implementing “Option B+” in Cameroon” is my original research conceived 
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manuscript entitled “Retention-in-care and reasons for discontinuation of lifelong 
antiretroviral therapy in a cohort of Cameroonian pregnant and breastfeeding HIV-positive 
women initiating "Option B+" in the South West Region” has passed the first review and 
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